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1. Abstract 
 
Mutations in the gene coding for the ATP binding cassette protein A3 (ABCA3) are 
known as the most frequent genetic cause of fatal neonatal respiratory distress syndrome 
and chronic interstitial lung disease (ILD) of children. ABCA3 transporter is localized to the 
limiting membrane of lamellar bodies, organelles for assembly and storage of pulmonary 
surfactant in alveolar epithelial type II cells. It transports surfactant phospholipids into 
lamellar bodies and is essential for their biogenesis. ABCA3 mutations can result in either 
functional defects of the correctly localized ABCA3 or trafficking/folding defects where 
mutated ABCA3 remains in the endoplasmic reticulum (ER).  
This study showed previously not examined cellular dysfunction in cultured lung 
epithelial A549 cells overexpressing the three ABCA3 mutations R43L, R280C and L101P. 
All three mutations were found in children with ABCA3-associated lung disease either with 
fatal neonatal respiratory distress syndrome (L101P and R43L) or chronic pediatric ILD 
(R280C). Cell biology of R43L and R280C mutations was studied here for the first time. 
L101P mutation was used as a known example of the trafficking/folding defect leading to the 
ER retention of ABCA3 protein.  
Human lung epithelial A549 cells were transfected with vectors containing wild type 
ABCA3 or one of the three ABCA3 mutant forms, R43L, R280C and L101P, C-terminally 
tagged with YFP or hemagglutinin-tag. Localization/trafficking properties were analyzed by 
immunofluorescence and ABCA3 deglycosylation. Uptake of fluorescent NBD-labeled lipids 
into lamellar bodies was used as a functional assay. ER stress and apoptotic signaling were 
examined through RT-PCR based analyses of XBP1 splicing, immunoblotting or FACS 
analyses of stress- and apoptosis-proteins, Annexin V surface staining and determination of 
the intracellular glutathion level. Induction of epithelial-mesenchymal transition (EMT) was 
assessed by immunoblotting. 
It was demonstrated that two ABCA3 mutations, which affect ABCA3 protein 
trafficking/folding and lead to partial (R280C) or complete (L101P) retention of ABCA3 in the 
ER compartment, can elevate ER stress and susceptibility to it and induce apoptosis in A549 
cells. A549 cells expressing L101P additionally gain a mesenchymal phenotype. R43L 
mutation, resulting in a functional defect of the properly localized ABCA3, had no effect on 
intracellular stress and apoptotic signaling.  
These data suggest that expression of partially or completely ER localized ABCA3 
mutant proteins induce raised intracellular stress and apoptotic cell death of the affected 
cells, which are factors that might contribute to the pathogenesis of genetic ILD via a fatal 
ER-stress/apoptosis/fibrogenesis-axis. 
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2. Zusammenfassung 
Mutationen im ATP-Bindekassetten-Protein A3 (ABCA3) sind die häufigsten bekannten 
genetischen Ursachen für schwere Atemnotsyndrome bei Neugeborenen und für chronische 
interstitielle Lungenerkrankungen (ILD) im Kindesalter. Der ABCA3-Transporter ist in der äußeren 
Membran von Lamellarkörperchen lokalisiert, dem Speicherort von Surfactant in Alveolar Typ II 
Zellen. Er transportiert Phospholipide in die Lamellarkörperchen und ist essentiell für deren 
Bildung. ABCA3 Mutationen zeigen entweder einen funktionellen Defekt des korrekt lokalisierten 
ABCA3 Proteins oder einen Transport-/Proteinfaltungs-Defekt des mutierten ABCA3 Proteins, 
welches  im Endoplasmatischen Retikulum (ER) verbleibt. 
 Diese Studie zeigt die zuvor noch nicht untersuchten zellulären Fehlfunktionen der  
Lungenepithelzellen A549, welche die drei ABCA3 Mutationen R43L, R280C und L101P 
überexprimieren. Alle drei Mutationen wurden bei Kindern mit einer ABCA3-assoziierten 
Lungenerkrankung gefunden. Diese Kinder waren entweder an einem schweren neonatalen 
Atemnotsyndrom (L101P und R43L) oder einer chronischen kindlichen ILD (R280C) erkrankt. 
Zellbiologische Untersuchungen der R43L und R280C Mutationen wurden in dieser Studie zum 
ersten Mal durchgeführt. Die L101P Mutation wurde als bekanntes Beispiel eines Transport-/ 
Proteinfaltungs-Defektes verwendet, der zu einer Akkumulation des ABCA3 Proteins im ER führt.  
 Humane Lungenepithelzellen A549 wurden mit Vektoren transfiziert, die das ABCA3-WT 
Protein oder eine der drei ABCA3 Mutationen R43L, R280C und L101P, C-terminal fusioniert mit 
einem YFP oder Hämagglutinin-Tag, enthalten. Lokalisations-/Transport-Eigenschaften wurden 
mittels Immunfluoreszenz und eines Deglykosylierungs-Assays analysiert. Die Aufnahme von 
fluoreszierenden NBD-markierten Lipiden in Lamellarkörperchen wurde als funktioneller Assay 
angewandt. ER Stress und Apoptosesignale wurden untersucht anhand von RT-PCR 
basierenden Messungen des XBP1-Splicing, Immunoblotting und FACS-Analysen von Stress-/ 
Apoptose-Proteinen, Annexin V-Färbung und Bestimmung des intrazellulären Glutathion-
Gehaltes. Die Induktion der epithelialen-mesenchymalen Transformation wurde anhand von 
Immunoblotting bemessen. 
 Es zeigte sich, dass in A549 Zellen die zwei ABCA3 Mutationen, die Transport/Faltung 
des ABCA3 Proteins beeinflussen, zu partiellem (R280C) oder vollständigem (L101P) Verbleiben 
von ABCA3 im ER führen, ER Stress sowie die Anfälligkeit dafür erhöhen und Apoptose 
induzieren. A549 Zellen, die L101P überexprimieren, erlangten zusätzlich einen mesenchymalen 
Phänotyp. Die R43L Mutation zeigte einen funktionellen Defekt des richtig lokalisierten ABCA3 
Proteins und hatte keinen Effekt auf intrazellulären Stress und Apoptosesignale. 
 Diese Daten lassen vermuten, dass die Expression von teilweise oder vollständig im ER 
verbleibendem mutiertem ABCA3 Protein in den betroffenen Zellen erhöhten intrazellulären 
Stress und Apoptose verursacht und damit ein Faktor ist, der zu der Pathogenese genetischer 
ILD über eine ER-Stress/Apoptose/Fibrogenese-Achse beitragen kann. 
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3. Introduction 
 
3.1 Pediatric interstitial lung disease (pILD) 
 
Interstitial lung disease (ILD) in infants and children, also called diffuse parenchymal 
lung disease (DPLD), comprises a heterogeneous group of rare respiratory disorders 
affecting the pulmonary interstitium (1). Some entities are unique to children (1). These 
disorders are associated with high morbidity and mortality (2). Limited by the rarity of 
pediatric interstitial lung disease (pILD), these disorders are still poorly investigated and 
understood. Common characteristics of pILD are respiratory symptoms such as dyspnea, 
tachypnea, cyanosis, cough, wheezing and haemoptysis, that persist longer than three 
months, accompanied by abnormal pulmonary function tests (PFTs), impaired gas exchange, 
frequent respiratory infections and infiltrates on the chest x-ray (1,3). 
 
3.1.1 Epidemiology of pILD 
 
To date, epidemiological analysis of pILD is difficult to obtain and the development of 
prospective trials requires a systematic multicenter cooperation. Current knowledge is based 
on case reports presenting patients´ clinical features and course of disease. The estimative 
prevalence of ILDs in children is much lower than reported in adults (4-7): A national survey 
in the United Kingdom and Ireland revealed an estimated prevalence of 3,6 cases/million (4). 
A study conducted in Germany assessed an incidence of 1,32 new cases of pILD per 1 
million of children per year (2). Parental consanguinity is confirmed in pILD in 7 % (8). 
Furthermore, in reviewing the family history it was shown that siblings suffered from similar 
disease in 10 %, suggesting a genetic influence (8). One main group of pILD is related to 
genetic surfactant dysfunction (2,9, Fig.1). Among these genetic surfactant abnormalities 
mutations in the ABCA3 gene are most frequent (2). 
 
 
 
 
 
 
 
 
 
 
Fig.1: Distribution of pediatric ILD in Germany. pILD are classified into two groups: entities occurring in infants (1-4) and at all 
ages (5-8). In infants, surfactant dysfunction disorders are the most prevalent entities, whereas ABCA3 mutations were the most 
frequent mutations in genes leading to surfactant abnormalities. According to (2) 
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3.1.2. Classification of pILD 
 
Many attempts were made on an accurate classification scheme of pILD. For a long 
time, pILD was tried to fit into the adult´ s classification. Limited by different disease 
frequency, histopathological features and clinical outcome a direct adaption of the adult 
scheme failed.  
A novel classification scheme of pILD was proposed by Deutsch and coworkers (10). 
For that multicenter study lung biopsies of 187 affected children less than 2 years old were 
collected from 1999 to 2004 in North America. Deutsch and coworkers provide a 
categorization scheme of almost all known entities in pILD (Fig.2). It mainly comprises two 
groups: entities prevalent in infants and entities in all ages. As shown in Figure 2 both groups 
consists of four subgroups. In entities seen in neonates and infants, the subgroups contain 
diffuse developmental disorders, alveolarization abnormalities, specific conditions of 
undefined etiology and surfactant disorders. Essential for surfactant production are the genes 
for the surfactant protein B and C gene (SFTPB and SFTPC) and the ATP- binding cassette 
protein A3 (ABCA3) gene. Therefore, abnormalities in these genes are involved in surfactant 
dysfunction and cause respiratory disease. Entities at all ages include disorders related to 
systemic diseases, in immune-intact hosts, in immunocompromised hosts and disorders 
masquerading as ILD. 
 
 
Diffuse Lung Disease in Childhood 
Infants All Ages 
• Diffuse developmental disorders • Disorders related to systemic 
disease processes 
• Growth abnormalities • Disorders to the normal host 
• Specific conditions of undefined 
etiology, e.g. neuroendocrine 
cell hyperplasia or pulmonary 
interstitial glycogenesis 
• Disorders of the 
immunocompromised host 
• Surfactant disorders as 
surfactant protein B or C 
mutations, ABCA3 mutations 
• Disorders masquerading as 
ILD 
 
Fig.2: Classification of diffuse lung disease in children. This scheme provides a categorization of almost all known diffuse 
pediatric lung disease entities two groups: entities prevalent in infants and occurring at all ages. According to (10). 
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3.1.3 Genetic surfactant dysfunction disorders 
 
Pulmonary surfactant is a complex mixture of 90 % lipids (mostly phospholipids) and 
10 % surfactant-specific proteins A-D (11). It forms a film at the alveoli-air interface to reduce 
surface tension in the alveoli and to prevent alveolar collapse at the end of expiration. 
Alveolar type II cells (AT II) produce the surfactant mixture, which is stored within 120-180 
lamellar bodies until it is secreted (12-14). Lamellar bodies (LB) are characterized by multiple 
lamellar structures and one surrounding outer membrane (15, Fig.3).  
 
 
 
 
 
 
 
 
 
 
Mutations in the genes encoding for surfactant protein B (SP-B) and C (SP-C) as well 
as for the ATP-binding cassette protein A3 (ABCA3) were found in genetic surfactant 
deficiency syndromes (16-22). In 1993, for the first time a genetic mechanism for fatal 
respiratory distress syndrome (RDS) was discovered in a full-term infant. An autosomal 
recessively inherited mutation in the SP-B gene (SFTPB) was identified to be the underlying 
cause for surfactant protein B deficiency and genetic respiratory disease (23). Since then, an 
increasing number of mutations in SFTPB have been identified in full-term infants presenting 
with severe RDS and a rapid progressive and fatal course (24-26). Also mutations in the SP-
C gene (SFTPC) have been identified in newborns with RDS, but usually in SFTPC-
associated lung disease, disease onset occurs later than in neonatal period and patients 
present with a more chronic clinical course (16,18).  
Recently in 2004, when mutations in SFTPB or SFTPC have been excluded in 
newborns with neonatal lung disease unresponsive to exogenous surfactant, mutations in the 
ABCA3 gene were recognized as a cause of lethal RDS and imbalance in surfactant 
composition (22, 27). Today, mutations in the ABCA3 gene are known to cause not only fatal 
neonatal RDS but also chronic pILD in older children with a milder course (21). With more 
than 500 identified mutations, ABCA3 deficiency is the most frequent known cause of genetic 
ILD today (own unpublished data, 22, 27, 28).  
 
Fig.3: A representative electron micrograph of a lamellar 
body in A549 cells (provided by our research group). 
LBs show many regular concentric lamellae and appear 
like “onion-skin” (diameter: 0.1-2.4 μm). 
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3.1.4 Clinical diagnostics and therapy of pILD 
 
Clinical signs and symptoms like hypoxia, tachypnea, dyspnea, retractions, failure to 
thrive, crackles, cough, wheeze and frequent respiratory infections are observed in infants 
and children with suspected diffuse parenchymal lung disease, but clinical presentation 
varies from asymptomatic to severe respiratory distress (29). As a first diagnostic study when 
plain chest x-ray provides insufficient insight, a high-resolution CT (HRCT) can show the 
most common feature of widespread ground-glass opacities, secondary honeycomb, 
interlobular septal and air wall thickening and fibrotic lesions (29). Lung biopsy and the 
histological analysis of lung tissue are often indispensable and crucial for the final diagnosis 
of pILD (8). According to the latest data and the increasing number of genetic pILD (2, 30, 
31), the diagnostic workup of newborns and infants with probable genetic-associated lung 
disease should also include a DNA blood sample testing for mutations in the genes encoding 
for SP-C, SP-B and ABCA3. 
The current treatment of pILD is based on the clinical experience from small case series 
in children and from clinical trials in adults. Affected newborns with severe respiratory 
distress onset directly after birth require mechanical ventilation and application of exogenous 
surfactant. Generally, therapy aims for the suppression of inflammation and prevention of 
fibrogenesis (29). Over half of the patients receive systemic steroids and a minor group 
profits additionally from further immunosuppressive, anti-inflammatory or anti-fibrotic drugs 
as hydroxychloroquine, azathioprine and methrotrexate for weeks, months or years (2, 10). 
As children are sometimes unresponsive to drug-therapy, the ultimate option is lung 
transplantation. Today controlled clinical trials in children are conducted for evidence based 
treatment recommendations.  
 
 
3.1.5 Prognosis of pILD 
 
Today morbidity and mortality in pILD is pretty high, but also varying between different 
entities. The overall mortality in pILD is around 15% and 21% (9, 29). Whereas better 
prognosis and lower mortality is reported for children with neuroendocrine cell hyperplasia of 
infancy or pulmonary interstitial glycogenesis, other forms of pILD, especially genetic 
surfactant deficiency syndromes, are associated with worse outcome. Particularly for 
ABCA3-related lung disease mortality is pretty high (10, 22).  
 
 
 
 
7
3.2  ATP- binding cassette protein A3 (ABCA3)  
 
3.2.1 ABC transporters 
 
ABCA3 is a member of the large family of the ATP-binding cassette (ABC) 
transporters. The ABC transporters, including family A-F, are transmembrane proteins that 
utilize energy of ATP hydrolysis to drive the transport of a variety of substrates across 
biological cellular or intracellular membranes (32, 33). The ABC family shares a common 
structure. It is characterized by the full transporter structure with 12 transmembrane domains, 
two cytoplasmic ATP-binding sides and various conserved motives (Fig.4).  
 
 
Fig.4: Structure of an ABC-transporter: Representative of the twelve transmembrane domains (TMD), here two TMDs are 
shown (TMD1 and TMD2) with the two cytoplasmic nucleotide-binding domains (NBD1 and NBD2). ATP-hydrolysis drives the 
transport of the substrates (S) (According to (34)). 
 
 
In humans, the A subfamily consists of the members ABCA1 to ABCA13. Many 
members play similar roles especially in lipid transport. For example, ABCA1 and ABCA4 
transport cholesterol and phosphatidylethanolamine, respectively (35-37).  
Several members of the ABC superfamily are well known for their role in inherited 
disorders (38). Particularly, the most frequent genetic lung disease named cystic fibrosis is 
caused by mutations in ABCC7 gene, encoding for CFTR. In the A subfamily not only ABCA3 
deficiency is recognized as a cause for genetic disease, also other members have been 
known for associated inherited disorders before. For example, mutations in the human 
ABCA1 gene cause Tangier disease with the accumulation of cholesterol, HDL deficiency, 
early onset of arteriosclerosis and peripheral neuropathy and mutations in the human ABCA4 
gene cause Stargardt´ s macular dystrophy (36, 37, 39, 40).  
 
 8
3.2.2 General on the ABCA3 protein 
 
First, ABCA3 protein was found in thyroid tissue (33), followed by a wide variety of 
other tissue as brain, heard, kidney, stomach, pancreas and platelets. However, its highest 
protein expression levels are found in lung tissue, particularly in alveolar type II cells (41-43). 
The expression level of ABCA3 is developmentally regulated, increases prior to birth and is 
upregulated in a glucocorticoid-dependent manner in vitro (41, 43, 44).  
The ABCA3 protein is encoded by a single gene mapped to human chromosome 
16p13.3 with a size of 80 kB, transcribed into 6500bp mRNA and translated into a 1704 
amino acid protein (45). Mutations in ABCA3 gene are inherited in an autosomal-recessive 
manner. According to the general structure of an ABC transporter, ABCA3 consists of 12 
transmembrane domains, two extracellular loops (EL) and two nucleotide-binding domains 
(NBD) (Fig.5).  
 
 
Fig.5: Structure of the ABCA3 transporter in a lipid bilayer membrane (yellow): According to the general structure of an ABC 
transporter, ABCA3 is a transporter with 12 transmembrane domains (green), two extracellular loops (EL) and two nucleotide-
binding domains (NBD). More than 500 mutations are identified, some of them are colored blue (frameshift mutation), red 
(missense mutation) or black (nonsense mutation) in this scheme. The author of this model is Dr. Suncana Kern, she provided it 
to our research group and I use it with her permission. 
 
 
 
3.2.3 Function of ABCA3 
 
3.2.3.1 Localization and lamellar body biogenesis 
 
ABCA3 is highly expressed in alveolar type II cells (ATII) and localizes to the limiting 
membrane of lamellar bodies (LBs) (41, 42), intracellular organelles for assembly and 
storage of pulmonary surfactant. ABCA3 protein plays a key role in the biogenesis of LBs 
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and is crucial for their morphology. In electron microscope studies of healthy lungs, LBs 
appear as “onion-skin” like, regular concentric arranged lamellae (Fig.3). In children with 
ABCA3 mutations, LB morphology is abnormal (22). Immature LBs with “tightly packed 
concentric membranes” (46) show small electro-dense bodies within, appearing as “fried-
egg” inclusions (46-48). This LB-morphology is characteristic for ABCA3 deficiency and LB 
morphology can be an indicator to distinguish between the entities of genetic surfactant 
dysfunction disorders. Whereas in SP-B deficiency large and disorganized composite bodies 
and multiple vesicular inclusions appear (49, 50), in SP-C deficiency vesicular bodies with 
aggregates of small vesicles with electro-dense cores can be observed  (51-53).  
Furthermore, ABCA3 protein is not only essential for LB morphology but also for their 
formation. In Abca3 knock-out mice presenting with acute respiratory failure normal and 
mature LBs are absent and mice die within hours after birth (54-56). Moreover, in in vitro 
studies, the ABCA3 overexpression in kidney cells (HEK293 cells) induces de novo synthesis 
of lamellar body-like vesicles (57).  
 
 
3.2.4.2 ABCA3 is a lipid transporter 
 
ABCA3 expression is not only essential for biogenesis of mature LBs as the 
intracellular organelle for assembly and storage of surfactant, but is also responsible for the 
composition and homeostasis of pulmonary surfactant. ABCA3 is a lipid transporter, which 
drives the transmembrane translocation of surfactant phospholipids from the cytoplasm into 
LBs. In vitro studies show that ABCA3 overexpression promotes the uptake of natural 
choline-phospholipids into LBs (58, 59). When ABCA3 expression is down-regulated by 
siRNA, phosphatidylcholine, sphingomyelin and cholesterol uptake are significantly 
decreased (57). Furthermore, in human and mice with ABCA3 deficiency, 
phosphatidylcholine species and phosphatidylglycerol are dramatically reduced in 
bronchoalveolar lavage and lung tissue, respectively (27, 54, 60). Thereby surfactant mixture 
looses its function and surface tension is increased (27). Since the last steps in SP-B and 
SP-C processing occur inside of functional LBs, ABCA3 deficiency in human and mouse 
leads to accumulation of SP-B and SP-C precursors and lack of mature forms (28, 55, 60).  
 
 
3.2.3.1.1 Categorization of ABCA3 mutations 
 
Mutations in the ABCA3 gene are classified into two categories (61): Type I mutations 
are characterized by abnormal intracellular ABCA3 protein localization and impaired 
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intracellular ABCA3 protein trafficking. In type II mutations, the ABCA3 transporter shows 
decreased ATP-binding capacity/ decreased ATP-hydrolysis activity but proper trafficking to 
LBs. Table 1 gives an overview of mutations that were found in patients and which have 
been analyzed and classified in in vitro studies before.  
 
Table 1: Overview of ABCA3 mutations examined in previous studies in vitro. 
Type I (abnormal localization) Type II (impaired ATP-hydrolysis) 
L101P (57, 61)  N568D (57, 59, 61)  
L982P (61) G1221S (57, 61)  
W1142X (61) L1580P (61) 
Q1591P (61) E292V (34, 61)  
L1553P (61) E690K (62) 
Ins1518fs/ter1519 (61) T1114M (62) 
Q215K (34)  
 
 
 
3.2.4 ABCA3 in lung disease 
 
3.2.4.1 Early and late onset of lung disease 
 
Current data show that ABCA3 mutations are the most frequent known cause of 
genetic ILD. In 2004, ABCA3 mutations were discovered in full-term neonates with fatal 
neonatal lung disease and symptoms of surfactant deficiency occurring shortly after birth 
(22). Morbidity and mortality in these ABCA3-related surfactant deficiency syndromes is 
pretty high (10). Recently, mutations in ABCA3 gene have also been associated with chronic 
lung disease in older children (21, 66, 68, 71), demonstrating that children with ABCA3 
mutations can also survive well beyond infancy to early adulthood with a diagnosis of pILD. 
Currently, an increasing number of case reports about patients with ABCA3 deficiency is 
published and raises the number of identified ABCA3 mutations (21, 22, 27, 28, 46, 48, 63-
73). To the date, our research group knows more than 500 mutations, including some 
unpublished data. Similar to SP-C deficiency, ABCA3-related lung disease is complex and 
heterogeneous in histopathology and symptom severity. The disease onset varies from 
directly after birth, early in infancy or later in childhood, sometimes following the exposure to 
environmental stressors (71). However, the exact mechanism leading to the milder 
phenotype in pILD caused by ABCA3 mutation compared with the lethal cause in RDS is not 
yet known. 
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3.2.4.2 Genotype-phenotype interplay 
 
Some data show a genotype-phenotype correlation in lung disease caused by ABCA3 
mutations, suggesting that patients with a type I homozygous ABCA3 mutation or with type I / 
type II compound heterozygous mutations die within the neonatal period, whereas patients 
with a type II homozygous ABCA3 mutation survive beyond neonatal period und occur with 
milder phenotype (21, 22). In contrast, some clinical experience on ABCA3-related lung 
disease is inconsistent with the idea of a genotype-phenotype correlation (47, 48, 62, 66, 
unpublished data from our research group), demonstrating a significant phenotypic 
heterogeneity of lung disease associated with ABCA3 mutations from fatal RDS to milder 
course in pILD that is independent from genotype. However, the mechanism leading to 
phenotypic heterogeneity of lung disease associated with ABCA3 deficiency is still poorly 
understood. 
 
 
3.2.4.3 Outer stressor  
 
 Since the variety of clinical appearance in ABCA3 deficient patients can not completely 
be explained by the genotype-phenotype correlation, clinical experience suggests a link 
between the late onset of genetic ILD and exposure to outside stress factors, such as 
respiratory infections and cigarette smoke (71), speculating that outer stressors accelerated 
the patients´ underlying disease course.  
 
 
3.2.4.4 Histopathological pattern 
 
Hyperplastic alveolar type II cells, accumulation of alveolar macrophages and 
proteinaceous material in distal air spaces characterize the histological pattern in patients 
with ABCA3 deficiency (22, 47). In further course of the disease, interstitial thickening and 
fibroblast proliferation in interstitial spaces are found in the histological pattern (46, 47). Lung 
biopsy findings show the histology of CPI (chronic pneumonitis of infancy), DIP 
(desquamative interstitial pneumonia), NSIP (nonspecific interstitial pneumonia), PAP 
(pulmonary alveolar proteinosis) and pulmonary fibrosis, whereas DIP is seen in the majority 
of the patients (47).  
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3.2.4.5 Therapy 
 
To the date, there are no causative therapeutic options available for ABCA3-related 
surfactant deficiency. The therapeutic strategy concentrates on the reduction of symptoms 
and the limitation of inflammation and fibrogenesis. Oxygen application, mechanical 
ventilation and exogenous surfactant application can help to stabilize vital function 
temporarily in case of acute respiratory distress. Symptomatic treatment of ABCA3-related 
lung disease includes drugs, which are administrated in the management of ILD as well like 
steroids and hydroxychloroquine (29). The ultimate therapeutic option in end-stage 
respiratory failure is lung transplantation.  
 
 
3.2.4.6 ABCA3 mutations in this study 
 
In this study, the clinically relevant ABCA3 mutations R43L, R280C and L101P, which 
either were found in newborns with respiratory distress syndrome (RDS) or in children with 
chronic pILD, were examined. Table 2 provides an overview on the patients, their clinical 
feature and outcome. 
Brasch and colleagues reported from a full-term female newborn, delivered 
uneventfully after a normal pregnancy (28). Directly after birth she developed severe 
respiratory distress, required intense supportive care, mechanical ventilation and exogenous 
surfactant application and died at the age of 47 days. The patient had a sibling who has died 
briefly after birth from respiratory failure before. Analyzing the ABCA3 gene, which is 
inherited in an autosomal-recessive fashion, in the healthy parents and one healthy sibling 
showed that they are heterozygous for the G  T mutation at nucleotide 128 (first 
extracellular loop), which causes an R43L (Arg > Leu) amino acid substitution (Fig.6). Lung 
biopsy of the patient revealed chronic pneumonitis of infancy, absent ABCA3 protein 
expression, reduced mature SP-B expression (SP-C analysis not done) and electro-dense 
bodies in type II pneumocytes. Appropriate material for mutation analysis was not available 
from the patient. Furthermore, Somaschini (48) and Garmany (27) and coworkers, both 
reported from two full-term newborns that were compound heterozygote for the R43L 
mutation (R43L/R1482W and R43L/P264R, respectively) and had a similar clinical picture as 
the reported female patient above, including severe respiratory distress syndrome. Both 
newborns required intense supportive care. One patient died at the age of 30 days, the other 
patient received lung transplantation. The histological examination showed DIP and CIP, 
respectively (Table 2). 
Unpublished data from our research group include a female patient, 15 years old, 
presenting with milder respiratory symptoms consistent with chronic pILD. She was found to 
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be heterozygote for the R280C mutation. Lung biopsy showed DIP. She is still alive and in a 
stabile health condition that allows her an almost normal activity and life. None of her family 
members suffered from neonatal lung disease (Table 2). Besides, the R280C mutation was 
also found in a full-term male newborn, who suffered from unexplained respiratory distress 
within 24 hours after birth (27) (Table 2). Mechanical ventilation was insufficient and he died 
2 days after delivery. He had no family history of neonatal lung disease. Lung tissue was not 
available.  
The L101P mutation was found in two full-term newborns, siblings with consanguine 
parents, presenting with respiratory failure that occurred within hours after birth (48). Clinical 
and radiographic findings were consistent with surfactant deficiency and both newborns died 
within a month after birth. By sequencing analysis of the ABCA3 gene, homozygous 
substitution of proline for leucine in codon 101 (L101P) was found in both infants (Fig.6). 
Lung tissue was not available. 
While R43L and R280C mutations were examined in this study for the first time, 
L101P mutation was used as an example for a trafficking defect/ type I-mutation (22, 61). 
 
 
 
Fig.6: Localization of the ABCA3 mutations R43L, R280C and L101P within the ABCA3 transporter. R43L mutation is localized 
to the first extracellular loop at the border with the first transmembrane domain. L101P mutation localizes to the first extracellular 
loop. Depending on the topology software used, R280C mutation localizes either to the second transmembrane domain or to the 
second cytoplasmic loop. The author of this model is Dr. Suncana Kern, she provided it to our research group and I use it with 
her permission. 
 
 
 
The identified missense mutations R43L, R280C and L101P involved highly 
conserved codons and were not detected in at least 100 control samples from racially or 
ethnically matched controls (22, 27, 28, 48). 
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Table 2: Characteristics of patients with ABCA3 mutations analyzed in this study. 
 
Definition of abbreviations: RDS= respiratory distress syndrome, CPI= chronic pneumonitis of infancy, n.d.= not described,  
DIP= desquamative interstitial pneumonia, LTX= lung transplantation, n.a.= not available. 
 
 
 
 
3.3 How misfolded proteins disturb cell homeostasis 
 
3.3.1 Role of the endoplasmic reticulum 
 
The endoplasmic reticulum (ER) is an intracellular network of membranes consisting 
of interconnected tubules and vesicles with a wide variety of functions such as Ca2+-storage 
and -release, biosynthesis of secretory and membrane proteins, lipids and sterols, 
posttranslational modification of nascent polypeptides and their proper folding. Furthermore, 
proper protein folding of immature secretory and membrane proteins is a highly controlled 
process in the lumen of the ER. This procedure requires the presence of folding enzymes, 
quality control factors and chaperones that catalyze and assist in protein maturation and 
folding to their final confirmation (74). After further protein modification- and/or 
deglycosylation- processes the modified protein chains are transported into Golgi apparatus.  
 
 
 
Patient 
No. 
Gene/mutation Phenotype Family history/ 
Consanguinity 
Histological 
findings 
Outcome Reference 
1 n.a. 
Healthy parents 
+ sibling 
heterozygous for 
R43L 
RDS yes/ no CPI Death at the 
age of 47 d 
Brasch et al., 2006 (28)  
2 R43L/P264R RDS yes/ n.d. CPI LTX Garmany et al., 2006 (27)  
3 R43L/R1482W RDS no/ n.d. DIP Death: 30 
days after 
birth 
Somaschini et al., 2007 (48)  
4 R280C/wt RDS no/ n.d. n.a. Death: 2 
days after 
birth 
Somaschini et al., 2007 (48)  
5 R280C/wt Chronic 
pILD 
no/ no DIP alive Unpublished own data 
6 L101P/L101P RDS yes/ yes n.a. Death in 
neonatal 
period 
Shulenin et al.,2004 (22)  
7 L101P/L101P RDS yes/ yes n.a. Death in 
neonatal 
period 
Shulenin et al.,2004 (22)  
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3.3.2 Induction of the quality control system by unfolded proteins 
 
Failure of posttranslational protein modification and an increasing number of unfolded 
proteins retained within the ER lumen cause ER stress.  Therefore, the ER offers a 
cytoprotective quality control mechanism named the unfolded protein response (UPR). The 
UPR system prevents the cell from unfolded defect proteins exit the ER and induces cellular 
adaption to disturbed cell homeostasis (74, 75). Three mechanisms regulate cellular 
adaption: first, general inhibition of protein translation to decrease the protein load in the ER, 
second, transcriptional induction of genes encoding chaperones to maintain the protein-
folding capacity of the ER and third, the induction of proteins belonging to the ER-associated 
degradation (ERAD), that is responsible for the transport of misfolded proteins to the cytosol 
and subsequent degradation (76-79). If UPR fails to resolve ER stress and to restore cell 
homeostasis, apoptotic cell-death pathway is initiated (80). 
In non stressed cells, the binding protein (BiP)- also named glucose regulated protein 
(GRP78)- binds to the three UPR signal transducers that are localized to ER membrane to 
maintain them in an inactive state (81, Fig.8). Upon ER stress and accumulation of unfolded 
proteins in the ER lumen, BiP is released from the three UPR sensors to assist in protein 
folding. Thus, UPR sensors are activated to induce the cellular adaption to disturbed cell 
homeostasis.  
First UPR signal transducer, ionsitol-requiring enzyme 1 (IRE1), a transmembrane 
serine/ threonine receptor protein kinase, is activated upon accumulation of unfolded proteins 
in the ER lumen. IRE1 cleaves mRNA encoding for the basic leucine zipper transcription 
factor X-box binding protein 1 (XBP1), a key transcription factor of UPR elements, in the 
cytoplasm (82). The XBP1-mRNA is cleaved at two sites, the 5´ and 3´ fragments are ligated 
and a 26- base intron is cut off (82, Fig.7). The result is a translational frameshift and the 
active XBP1 transcription factor (83, 84). Active XBP1 is responsible for the transcription of 
genes encoding a wide variety of UPR elements such as chaperones and folding enzymes 
as well as ERAD elements (85, 86). Furthermore, IRE1 induces degradation of several 
mRNAs, thereby preventing the cells from a high protein load during ER stress (87).  
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Fig.7: Schematic representation of the splicing of XBP1 mRNA: Upon ER stress, a 26-base intron (nt) is cut off by IRE1, 5´and 
3´fragments are ligated, creating a translational frameshift and producing an active XBP1 transcription factor. (According to (84)) 
 
Second UPR sensor named activating transcription factor 6 (ATF6) regulates 
expression of genes encoding for ER quality control proteins (88). 
Third UPR sensor is the ER resident transmembrane protein kinase (PERK), which 
induces mRNA translation of approximately one third of the genes encoding for UPR proteins 
and activates a translation factor (eIF2alpha) that attenuates protein synthesis in general and 
initiates translation of genes with pro-apoptotic function (89). 
          
Fig.8: Overview of the UPR system and its elements. Upon the accumulation of unfolded proteins the UPR sensors ATF6, IRE1 
and PERK are activated by the release of BiP and induce a variety of mechanisms for the cellular adaption to a disturbed cell 
homeostasis: XBP1 splicing and activation as a transcription factor, upregulation of chaperones to assist in protein folding, 
induction of protein degradation and attenuation of general protein translation. (According to (90)). 
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3.3.3 Induction of apoptosis  
 
Prolonged ER stress caused by accumulation of unfolded proteins in the ER lumen and 
the inability to restore cell homeostasis induces programmed cell death (=apoptosis). 
Apoptosis is a highly conserved cellular mechanism. It is essential for cell selection, cell 
homeostasis and tissue morphogenesis. A wide variety of stimuli can trigger cell surface 
death receptors (extrinsic pathway) or initiate the intrinsic pro-apoptotic pathway via 
mitochondria stimulation. Upon ER accumulation of misfolded proteins the three UPR 
sensors not only initiate cytoprotective mechanisms, but also contribute to the induction of 
programmed cell death via upregulation of pro-apoptotic proteins such as CHOP, Ca2+-
release, induction of mitochondrial stress (mitochondrial apoptosis) and ER stress (80).  
Pro-apoptotic signals are transduced by a family of regulated proteolytic enzymes 
named caspases. Caspases are a family of highly conserved aspartate-specific cysteine 
proteases, which induce the pro-apoptotic pathway and contribute to the destruction of cell 
structures and mechanisms as well as to the deregulation of protein synthesis (91). The 
caspase-cascade is a complex signaling pathway. Most caspases are present in cells as 
longer inactive precursors and become sequentially activated by proteolytic cleavage through 
an active upstream caspase or through autocatalysis (91). In mammalian species, 15 known 
members are divided into two groups: initiator caspases, which are activated by death 
receptors, and effector caspases that cleave proteins involved in programmed cell death 
events.  The activation of the down-stream executioner caspase 3 can be either conducted 
by the initiator caspase 9 that is activated in a mitochondria-dependent signaling way 
(mitochondrial apoptosis) by increased intracellular stress (92) or by caspase 8 that is 
activated through stimulation of the surface death receptor Fas. The executioner caspases 3, 
6, 7 cleave proteins involved in DNA processing and several structural proteins.  
Among the known caspases, mouse caspase 12 (homologous to human caspase 4), 
localized to the ER membrane, is specifically cleaved when ER stress increases by 
continuous accumulation of unfolded proteins and calcium imbalance (93, 94). Cleavage of 
caspase 12 leads to the activation of caspase 9 and caspase 3 (95, 96), resulting in 
apoptotic cell death, in a surface death receptor- and mitochondria-independent apoptotic 
signaling pathway (Fig.9).  
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Fig.9: Scheme of the mechanism how ER stress causes apoptotic cell death: Increasing ER stress leads to the cleavage of the 
ER membrane-bound caspase 12 in mouse (homologous human caspase 4), which catalysis the cleavage of caspase 9. Active 
caspase-9 catalysis the cleavage of procaspase-3, thereby promoting the further conduction of apoptosis. (According to (96))  
 
 
Vital cells generate and maintain an asymmetric double layer cell membrane of 
uncharged and charged phospholipids species. The negatively charged phosphatidylserines 
(PS) are mainly located in the inner leaflet facing the cytosol. During apoptosis, plasma 
membranes loose their feature of asymmetry by externalization of PS to the outer leaflet of 
the plasma membrane in a caspase-dependent way (97). Expression of PS on the cell 
surface is a signal for macrophages for phagocytosis. Furthermore, Annexin V binds to 
negatively charged PS on plasma membranes of apoptotic cells and can be used as a 
Molecular Imaging agent in visualizing apoptotic cells in patients and in in vitro studies (98, 
99). 
 
 
3.5 ER stress and apoptosis contribute to disease pathogenesis  
 
Recent data show that prolonged accumulation of unfolded proteins within the ER 
accompanied by simultaneous failure of the UPR system contribute to the pathogenesis of 
several disorders, such as metabolic disease, atherosclerosis, neurodegenerative disease 
and conformational diseases (100-102). Furthermore, ER stress and apoptosis in alveolar 
type II cells play a role in lung disease, especially in pathogenesis of idiopathic pulmonary 
fibrosis (IPF) and genetic SP-C-associated pulmonary fibrosis (103-105). Moreover, in in 
vitro studies in lung epithelial A549 cells expressing SP-C mutations, which cause misfolding 
and aggregation of the SP-C pre-protein, ER stress increases, UPR is activated and 
apoptotic cell death is initiated (106). 
Fibrosis is one of the hallmarks documented in ABCA3-associated lung disease (21, 
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68, 71). Today, it is known that idiopathic pulmonary fibrosis is not primarily connected to 
chronic and unresolved inflammation and fibrosis can occur without inflammation (107). 
Fibroblastic foci in the lung may underlie areas of unresolved chronic alveolar epithelial 
injury, ongoing lung repair and abnormal wound healing (29, 107, 108). 
Under such conditions of epithelial micro-injury alveolar type II cells contribute 
significantly to the alteration of the normal lung architecture, aberrant tissue remodeling and 
fibrogenesis and induce activation and migration of fibroblasts (107). Recently, it was shown 
that ATII cells undergo epithelial-mesenchymal transition (EMT) under specific conditions 
and change their characteristics and morphology to a fibroblast-like feature (109). Thereby 
ATII may contribute to lung fibrogenesis as an additional source of myofibroblasts in the 
pathogenesis of ILD (110). Moreover, alveolar epithelial cells are responsible for the release 
of almost all pro-fibrotic cytokines and growth factors, such as TGF-ß1, IL-1ß, TNF-  and 
GM-CSF, and for the synthesis and release of enzymes that contribute to extracellular matrix 
(111, 112). TGF-ß1 is the most aggressive pro-fibrotic growth factor among these mediators 
and the amount of TGF-ß is related to the extent of fibrosis and induction of myofibroblasts 
(113). Besides, TGF-ß1 induce EMT in alveolar epithelial cells, which is characterized by the 
loss of epithelial marker E-Cadherin (ECAD), the gain of mesenchymal marker vimentin and 
transformation into myofibroblastic morphology (109, 114). In this way, alveolar type II cells 
can acquire fibroblast-like feature and play a role in the development of fibrosis in lung 
disease.  
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4. An objective 
 
ABCA3 protein is an ABC lipid transporter found in alveolar type II cells, where it 
localizes to the outer membrane of lamellar bodies which store surfactant. Current in vitro 
studies show that ABCA3 is essential for surfactant homeostasis and LB biogenesis. 
Mutations in the ABCA3 gene are the most frequent known genetic cause of RDS in 
newborns and of late onset chronic ILD in children with a higher prevalence than mutations in 
SPFTB or SPFTC. Even though clinical experience suggests a link between the late onset of 
genetic ILD and exposure to outside stress factors, such as respiratory infections and 
cigarette smoke, contributing mechanisms leading to phenotypic heterogeneity remain 
unknown.  
In order to elucidate mechanisms leading to pediatric ILD, I investigated the influence 
of three ABCA3 mutations, R43L, R280C and L101P, found in children with surfactant 
deficiency and chronic ILD, on induction of ER stress, apoptosis and fibrogenesis in lung 
epithelial A549 cells. 
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4. Materials 
 
4.1 Chemicals 
 
In general, chemicals were obtained from Sigma-Aldrich (München, Germany) and 
Merck (Darmstadt, Germany). Special chemicals were purchased as follows: Agarose for 
DNA gel electrophoresis from SERVA (Heidelberg, Germany), D-PBS, trypsin-EDTA solution 
and FBS from PAA Laboratories GmbH (Pasching, Austria) and BSA from Paesel and Lorei 
(Duisburg, Germany). RPMI media was purchased from Sigma-Aldrich (München, Germany) 
and LB-Agar as well as LB-Bouillon were purchased from Merck (Darmstadt, Germany). 
Antibiotics kanamycin, ampicillin and tunicamycin were obtained from Sigma-Aldrich 
(München, Germany). Recombinant human Tumor Necrosis Factor  (TNF- ) was obtained 
from Invitrogen (Freiburg, Germany) and Recombinant human Tissue Growth Factor 1 
(TGF- 1) was obtained from R&D systems (Abingdon, England). Vectashield Hard and Set 
Mounting Media with DAPI was obtained from Vector Laboratories (Burlingame, CA, USA). 
NBD-labeled lipids phosphatidylcholine (C12-NBD-PC) and phosphatidylethanolamine (C12-
NBD-PE) were purchased from Avanti Polar Lipids (Alabaster, AL) and other lipids from 
Sigma-Aldrich (München, Germany). 
 
 
4.2 Equipment 
 
Fluorescence microscope Axiovert 135 obtained from Carl Zeiss (Oberkochen, 
Germany) was used for immunofluorescence analysis. The evaluation of pictures was 
performed with the help of the software AxioVision Release 4.7.1 (Carl Zeiss, Oberkochen, 
Germany). Olympus FluoView FV 1000 confocal microscope was used for the analysis of the 
NBD-lipid uptake. 
BD FACSCanto II Flow Cytometer was used for the FACS assay and FACSDiva 
v6.1.3 for data analyses (BD Bioscience). 
For the chemiluminescence detection Diana III camera system and for densitrometric 
analysis software AIDA were purchased from Raytest (Straubenhardt, Germany). GraphPad 
Prism version 4 was obtained from GraphPad Software (La Jolla, CA, USA) for statistical 
analysis. 
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4.3 Enzymes and kits 
 
Enzymes and kits were purchased as follows: QuickChange Site-directed 
Mutagenesis Kit for site directed point mutagenesis and PfuUltra TM Hotstart Polymerase 
were purchased from Stratagene (La Jolla, CA, USA). Restriction enzymes: KpnI, EcorI, 
HindIII, ScaI, XbaI, XhoI, BglII, DpnI and the corresponding reaction buffers as well as 
EndoH and PNGaseF for deglycolysation assay were purchased from NewEngland BioLabs 
(Ipswich, MA, USA). T4-DNA ligase and corresponding reaction buffer were purchased from 
Fermentas (Burlington, Canada). DNA extraction from agarose gels was performed with the 
help of QIAquick Gel Extraction Kit (Qiagen, Hilde, Germany) and Ultrafree®-DA (Millipore, 
Billerica, MA, USA). Plasmid- DNA isolation was performed with either QIAprep Spin 
Miniprep Kit (Qiagen, Hilden, Germany) or with NucleoBond Xtra Midi EF from Macherey- 
Nagel (Düren, Germany). Cell culture was tested regularly for mycoplasma with the help of 
Venor GEM-Mykoplasma Detection Kit for conventional PCR. 
High Pure RNA Isolation Kit and DNase I, RNase free from Roche (Mannheim, Germany) 
were used for RNA-isolation. SuperScriptTMIII First Strand Synthesis System from Invitrogen 
(Freiburg, Germany) and Taq-polymerase from NewEngland BioLabs (Ipswich, MA, USA) 
were used for performance of RT-PCR. 
Transfection was performed with the help of transfection reagent ExGen 500 from 
Fermentas (Burlington, Canada). Complete protease inhibitor cocktail was purchased from 
Roche (Basel, Schweiz). Determination of protein concentration was conducted with Bio-Rad 
Protein Assay Kit from Bio-Rad Laboratories (München, Germany). For SDS-Page and 
Western Blotting following buffers as well as precast gels were obtained from Invitrogen 
(Freiburg, Germany): NuPage® MOPS SDS Running Buffer (20x), NuPage® MES SDS 
Running Buffer (20x), NuPage® Tris-Acetate SDS Running Buffer (20x), GF® LDS Sample 
Buffer (4x), Transfer Buffer (20x), NuPage® 10 % Bis-Tris Gel, NuPage® 3-8 % Tris-Acetate 
Gel and 7 % Tris-Acetate Gel. Immobilion-P Transfer Membrane, a PVDF-membrane, was 
purchased from Millipore (Billerica, MA, USA). ECL and HyperfilmTM ECL were obtained from 
GE-Healthcare (Buckinghamshire, UK). For the purpose of immunoblotting with anti-GFP 
antibody, the chemiluminescent immunodetection system WesternBreeze® was obtained 
from Invitrogen. 
IntraPrepTM Permeabilization Reagent from Beckman Coulter (Fullerton, CA, USA) 
was used for preparing samples for flow cytometer analysis. 
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4.4 Primers 
 
All primers were purchased from Metabion International AG (Martinsried, Germany). 
 
Table 3: List of primers for point mutagenesis or sequencing. 
Primer name Sequence 
ABCA3.R43L.For 5'-CATCTGGCTCCTCTTGAAGATTC-3' 
ABCA3.R43L.Rev 5'-GAATCTTCAAGAGGAGCCAGATG-3' 
ABCA3.R280C.For 5'-CATTGCCTGTGCTGTCGTG-3' 
ABCA3.R280C.Rev 5'-CACGACAGCACAGGCAATG-3' 
ABCA3.L101P.For 5’-CAGTGCGCAGGGCACCTGTGATCAAC-3’ 
ABCA3.L101P.Rev 5’-GTTGATCACAGGTGCCCTGCGCACTG-3’ 
ABCA3.HA.For 5'-GCCGCGGGTACCATGGATTACCCATACGATGTTCCAGATTACGCTGCTGCTGTGCTCAGC-3' 
 
 
Table 4: List of primers for RT-PCR. 
 
 
 
Primer name Sequence 
XBP1.For.1 5´-AAACAGAGTAGCAGCTCAGACTGC-3´ 
XBP1.Rev.1 5´-TCCTTCTGGGTAGACCTCTGGGAG-3´ 
18srRNA.For.1 5'-TCAAGAACGAAAGTCGGAGG-3' 
18srRNA.Rev.1 5'-GGACATCTAAGGGCATCACA-3' 
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4.5  Vectors 
 
pEYFP-ABCA3-WT was a kind gift of  the research group of Dr. Andreas Holzinger 
(Fig.10), pJET1/ABCA3-HA  of my colleague Dr. M. Woischnik, pUB6-hABCA3-HA-L101P of 
my colleague Eva Kaltenborn and pEGFP-N1-SPC-WT of Dr. Michael Beers. PuB6-V5-
His/LacZ was purchased from Invitrogen (Freiburg, Germany) and pmax-GFP from AMAXA 
(Köln, Germany). Other vectors were generated in this study (Table 5).  
 
Table 5: List of vectors. 
Vector Resistance in 
E.coli DH5  
Resistance in 
cells 
Major characteristics Size Source 
Pmax-GFP kanamycin none Not suitable for 
making stable clones 
3486 bp AMAXA 
pJET1/ABCA3-HA ampicillin Only effective 
in non 
transformed 
cells 
HA tagged is fused to 
C-terminal end of 
ABCA3 gene 
31228 bp M. Woischnik 
puB6/V5-His/LacZ ampicillin blasticidin Contains gene for ß-
galactosidase 
8500bp Invitrogen 
pEYFP-ABCA3-WT kanamycin G418 Gene, encoding für 
YFP-protein, is fused 
to C-terminal end of 
ABCA3 gene 
10146 bp 
 
A. Holzinger 
pEYFP-ABCA3-R43L kanamycin G418 Gene, encoding für 
YFP-protein, is fused 
to C-terminal end of 
ABCA3 gene 
10146 bp This study 
pEYFP-ABCA3-R280C kanamycin G418 Gene, encoding für 
YFP-protein, is fused 
to C-terminal end of 
ABCA3 gene 
10146 bp This study 
pEYFP-ABCA3-L101P kanamycin G418 Gene, encoding für 
YFP-protein, is fused 
to C-terminal end of 
ABCA3 gene 
10146 bp 
 
This study 
puB6-hABCA3-HA-WT ampicillin blasticidin HA tagged is fused to 
C-terminal end of 
ABCA3 gene 
10542 bp 
 
This study 
puB6-hABCA3-HA-R43L ampicillin blasticidin HA tagged is fused to 
C-terminal end of 
ABCA3 gene 
10542 bp 
 
This study 
puB-hABCA3-HA-R280C ampicillin blasticidin HA tagged is fused to 
C-terminal end of 
ABCA3 gene 
10542 bp 
 
This study 
puB6-hABCA3-HA-L101P ampicillin blasticidin HA tagged is fused to 
C-terminal end of 
ABCA3 gene 
10542 bp 
 
E. Kaltenborn 
pcDNA4-TO-ABCA3-HA-WT ampicillin blasticidin HA tagged is fused to 
C-terminal end of 
ABCA3 gene 
n.a. Provided by 
the group 
pEGFP-N1-SPC-WT kanamycin neomycin Gene, encoding für 
GFP-protein, is fused 
to C-terminal end of 
SP-C gene 
5371bp M. Beers 
n.a.: not avaiable 
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Fig.10: Vector map of pEYFP-N1 (BD Clontech): Wild type full length human hABCA3 cDNA without stop codon was cloned 
into EcoRI/AgeI sites of pEYFP-N1 plasmid to obtain pEYFP-N1-WT vector for expression of C-terminal ABCA3-YFP protein 
fusions. 
 
 
 
4.6 Antibodies 
 
Primary antibodies for Western Blotting or immunofluorescence were either 
purchased from Santa Cruz (Santa Cruz, CA, USA), Chemicon (Billerica, MA, USA), 
Clontech (Mountain View, CA, USA), Stressgene (Hamburg, Germany), Dianova (Hamburg, 
Germany), Cell Signaling (Danvers, MA, USA), R&D System (Abingdon, England) or Sigma- 
Aldrich (München, Germany) (Table 6). 
 
 
 26 
Table 6: List of primary antibodies used for Western Blotting (WB) or immunofluorescence (IF). 
Primary Antibodies Source Type, Host Dilutions for WB and IF 
anti-ß-actin – 
HRP conjugate 
Santa Cruz (Santa Cruz, CA, USA) monoclonal, mouse WB 1:10 000 
anti-calnexin Santa Cruz (Santa Cruz, CA, USA) polyclonal, goat WB 1:500; 
IF 1:200 
anti-Hsp 90 Santa Cruz (Santa Cruz, CA, USA) monoclonal, mouse WB 1:500 
anti-human CD 63 
(LAMP3) 
Chemicon (Billerica, MA, USA) monoclonal, mouse IF: 1:200 
anti-EEA-1 Santa Cruz (Santa Cruz, CA, USA) polyclonal, rabbit IF: 1:200 
anti-GM130 Santa Cruz (Santa Cruz, CA, USA) polyclonal, goat IF: 1:50 
anti-GFP: 
Living Colors R A.v. (IL-8) 
Clontech (Mountain View, CA, USA) monoclonal, mouse WB: 1:500 
anti- caspase 4 Stressgene (Hamburg, Germany) monoclonal, mouse WB: 1:500 
anti- caspase 3 Dianova (Hamburg, Germany) monoclonal, mouse WB: 1:133 
anti- BiP Cell Signaling (Danvers, MA, USA) monoclonal, rabbit WB: 1:1000 
anti- E-cadherin R&D System (Abingdon, England) monoclonal, mouse WB: 1:250 
anti- vimentin Sigma- Aldrich (München, Germany) monoclonal, mouse WB: 1:2000 
anti-HA-tag Roche (Basel, Schweiz) monoclonal, rat IF: 1:200 
 
 
Secondary antibodies used for IF were purchased from Invitrogen (Freiburg, Germany) 
(Table 7). 
 
Table 7: List of secondary antibodies used for IF.  
Antibody Excitation (nm) Emission (nm) Filter 
anti-goat IgG - Alexa 555(donkey) 555 565 III (CY3) 
anti-mouse IgG - Alexa 555(goat) 555 565 III (CY3) 
anti-rabbit IgG - Alexa 555(goat) 555 565 III (CY3) 
anti-rat IgG - Alexa 488(donkey) 495 519 III (green) 
anti-rat IgG - Alexa 555 555 565 III (CY3) 
 
 
Secondary antibodies used for WB were purchased from Invitrogen (Freiburg, Germany), 
Biozol (Eching, Germany) or Sigma- Aldrich (München, Germany) (Table 8). 
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Table 8: List of secondary antibodies used for WB. 
Secondary antibody Source Type, Host Dilution 
anti-goat IgG –HRP conjugate Biozol (Eching, Germany) Polyclonal, rabbit WB 1:10 000 
anti-mouse: WesternBreeze® - alkaline 
phosphatase conjugated 
Invitrogen (Freiburg, Germany) Not published Not published 
anti-rabbit IgG – HRP conjugate Sigma- Aldrich (München, Germany) Polyclonal, goat WB 1:10 000 
 
 
Antibodies for flow cytometry were purchased from BD Biosciences (San Jose, CA, USA) 
(Table 9). 
 
Table 9: List of antibodies used for flow cytometry. 
  Antibody Source Channel 
  anti-annexinV Cy5 BD Pharmingen TM III 
  anti-active-caspase 3 
  PE conjugated 
BD Biosciences II 
  PI BD Pharmingen TM II 
 
 
4.7 Bacterial strains and cell lines 
 
Escherichia coli DH5  were obtained from Invitrogen (Freiburg, Germany). Human 
lung carcinoma epithelial cell line A54p (ACC 107) was obtained from German Collection of 
Microorganisms and Cell Cultures (DMSZ, Braunschweig, Germany).  
 
 
5. Methods 
 
5.1. Molecular biological methods 
 
5.1.1 Cloning strategy: Generation of pUB6-ABCA3-HA vector 
 
In order to generate puB6-hABCA3-HA vector with hemagglutinin tag (HA-tag) fused 
to C-terminus of the ABCA3 gene, puB6/lacZ vector and pJet1/hABCA3-HA vector were 
transformed into E.coli DH5  competent cells. Plasmid-DNA of both was isolated, restricted 
through KpnI and XhoI and separated by gel electrophoresis. The following restriction 
products were extracted with the help of QIAquick Gel Extraction Kit and Millipore Ultrafree-
DA: a 5320 bp KpnI and xhoI fragment containing pUB6 vector and a 5150 bp KpnI and xhoI 
fragment containing hABCA3-HA gene. DNA was precipitated by ethanol and resuspended 
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in water. For ligation, vector and insert, in 3:1 ratio, were incubated with T4 ligase and 
corresponding reaction buffer first for 60 min at room temperature and second for 10 min at 
65 °C.  Products of ligation reaction were multiplied by transformation into E.coli DH5  
competent cells. Two negative controls, the first one without insert and the second one 
without insert and T4 ligase, were generated. When no bacterial colonies have grown in 
these negative controls, plasmid DNA of the positive clones was isolated and their sequence 
was confirmed by conventional sequencing. 
 
 
 
Fig.11: Vector map of pUB6/V5-His: Plasmid vector puB6-hABCA3-HA for expression of C-terminal fusions of ABCA3 with 
hemagglutinin tag (HA-tag) was produced by modification of pUB6/V5-His vector. Own illustration according to a model from Dr. 
Suncana Kern. 
 
 
 
5.1.2 Site-directed point mutagenesis 
 
Site-directed point mutagenesis was performed with the help of QuickChange Site-
directed Mutagenesis Kit (Stratagene, La Jolla, California, USA) as recommended by the 
manufacturer. The following cycling parameters as shown in Table 10 were used for the 
introduction of point mutations into pEYFP-ABCA3- and pUB6-ABCA3-vectors. 
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Table 10:  Optimal conditions for PCR in this study. Annealing temperature for introduction of the mutation L101P into pEYFP-
ABCA3- vector was 52°C.  
 
Time Temperature Cycles 
5 min 95 °C 1 
30 sec. 95 °C 12 
1 min 52 °C 12 
20 min 68 °C 12 
10 min 68 °C 1 
 
Point-mutagenesis products were digested with DpnI at 37 °C for 1 hour. DpnI is an 
endonuclease that specifically digests methylated and hemimethylated DNA, which is 
exclusively present in parental and non-mutated DNA template from bacterial strains (115). 
This specific digestion permits selection of mutation-containing synthesized DNA and 
prevents transformation of non-mutated DNA into E.coli DH5 . Point-mutagenesis products 
were subjected to a 0.8 % agarose gel. 
 
 
5.1.3 DNA-sequencing 
 
DNA-sequencing was conducted by Metabion International AG (Martinsried, 
Germany). 
 
 
5.1.4 E.coli DH5 culture 
 
DH5  strain were grown on LB-Agar or in LB-Bouillon at 37°C. Media were 
supplemented with 30 mg/ml of kanamycin or 100 mg/ml of ampicillin when necessary. For 
subsequent plasmid-DNA isolation, 5 ml of cells were grown in LB-Bouillon at 37 °C with 
continuous shaking overnight.1 ml of the preculture was inoculated into 100 ml of LB-Bouillon 
and was grown further to optical density OD 600: 0.5-0.6. 1 ml of this overnight culture 
supplemented with 33 % of glycerin was stored as a stock solution at -80 °C.  
 
 
5.1.5 Generation of competent E.coli DH5 
 
E.coli DH5  competent cells were generated by CaCl2 -method. 5 ml of cells were 
grown in as an overnight preculture at 37 °C with continuous shaking. 1 ml of the preculture 
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was inoculated into 100 ml of LB-Bouillon and grown further to optical density OD 600: 0.5-
0.6. For further procedure, DH5  cells were incubated on ice. After 5 min of inoculation on 
ice, cells were collected at 4 °C and 5000 xg for 10 min. The cell pellet was resuspended in 
40 ml of ice cold Tfb I buffer (100 mM RbCl2, 50 mM MnCl2, 30 mM K-acetat, 10 mM CaCl2-
2H2O, 15% glycerin, pH 5) and incubated on ice for further 30 min. Cells were collected at 
4 °C and 5000 xg for 10 min, the pellet was disolved in ice cold Tfb II buffer (10 mM MOPS, 
10 mM RbCl2, 75 mM CaCl2-2H2O, 15 % glycerin, pH 6.8), was frozen in liquid nitrogen and 
stored at -80 °C.  
 
 
5.1.6 Transformation in E.coli DH5 
 
First, 15 l of point-mutagenesis products were added to DH5  cells and kept on ice 
for 30 min. Second, cells were heat-treated at 42 °C for 2 min and immediately cooled down 
on ice for 2 min. Third, cells were inoculated into 900 l of LB medium and grown at 37 °C for 
1 hour. Fourth, cells were collected at 5000 xg for 2 min. Cell pellet was dissolved in 100 l 
of media and cells were grown on LB agar with supplemented antibiotics at 37 °C overnight. 
One sample with not transformed DH5  cells was used as a negative control. When no 
colonies were detectable in negative controls, plasmid-DNA of transformed DH5  cells was 
isolated, restricted, subjected to 0.8 % agarose gel and sequence was confirmed by 
conventional sequencing. 
 
 
5.1.7 Plasmid-DNA isolation 
 
After transformation of pEYFP-ABCA3 or pUB6-ABCA3-HA vectors into DH5  strain 
an overnight culture of DH5  strain was prepared. DNA was isolated out of DH5  strain 
culture either with the help of QIAprep Spin Miniprep Kit or with NucleoBond Xtra Midi EF 
according to the protocol provided by the manufacturer. 
 
 
5.1.8 Restriction  
 
Restriction was performed with 500 ng of DNA, 1 U of enzyme/1 g of DNA and 10x 
corresponding reaction buffer were used. Mixtures were incubated at 37 °C for a minimum of 
three hours. Results were subjected to a 0.8 % agarose gel. 
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5.2. Mamalian cell culture 
 
5.2.1 Media and growth conditions 
 
A549 cells were incubated at 37 °C, 5 % of CO2 and grown in RPMI+ 10% FBS. In 
order to keep the lines in culture, cells were regularly split every third day in 1:10 ratio. Cells 
were used up to 20 passages. Where necessary, 10 ng/ml of tunicamycin (TM), 25 ng/ml of 
TNF-  and 0.05 ng/ml, 0.5 ng/ml or 5.0 ng/ml of TGF-  were added to media. 
 
 
5.2.2 Mycoplasma testing 
 
Mycoplasma testing was performed regularly with the help of Venor GEM-
Mycoplasma Detection Kit according to manufacturer´ s recommendations. 
 
 
5.2.3 Transfection of A549 cells 
 
A549 cells were grown up to 60-70 % confluence. Transfection was performed with 
ExGen 500 and optimized based on the protocol provided by the manufacturer (Fermentas, 
Burlington, Canada). 48 hours after transfection, immunofluorescence signal was recognized 
(Fig.12) and cells were collected for further experiments. 
 
  
Fig.12: Transfection of A549 cell line with pEYFP-ABCA3-WT. 
 
 
5.3. Biochemical methods 
 
5.3.1 Whole cell lysates preparation 
 
To prepare whole cell lysates, A549 cells were trypsinized and subsequently 
incubated with RIPA- buffer (containing: 0.15M NaCl, 1% Triton-X-100, 0.5% Sodium 
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deoxycholate, 0.1% SDS, 50 mM Tris, 5 mM EDTA, supplied with Complete protease 
inhibitor cocktail) for 30 min followed by sonication for 15 sec and incubation on ice for 
further 15 min. To remove nuclei and cell debris, samples were centrifuged at 4 °C and 
1000 xg for 30 min. Supernatant was frozen at – 80 °C.  
 
 
5.3.2 Crude membrane preparation 
 
A549 cells were grown to confluence, once washed with PBS, covered with 1 ml of 
ice-cold homogenization buffer (PBS supplemented with 1 mM EDTA and Complete 
protease inhibitor cocktail from Roche) and subsequently scraped off with a cell scraper on 
ice. Cells were broken in a 2 ml glass Potter Elvehjem homogenizer with 30 strokes while 
keeping the homogeniser constantly on ice. The homogenised sample was transfered in a 
fresh 1.5 ml tube and was sonicated for 30 sec. To remove nuclei and cell debris, samples 
were centrifuged at 4 °C and 700 xg for 10 min. The post-nuclear supernatant was 
centrifuged at 4 °C and 100.000 xg for one hour to obtain the crude membrane fraction in 
form of a pellet. This pellet was resuspended in 20 ml of ice cold resuspension buffer (25 mM 
HEPES/NaOH pH 7.0, Complete protease inhibitor cocktail) and stored at -20 °C.   
 
 
5.3.3 Determination of protein concentration 
 
Protein concentration of isolated membrane fraction and whole cell lysates were 
determined by Bradford protein assay with the help of Bio-Rad Protein Assay Kit (Bio-Rad 
Laboratories, München, Germany). 
 
 
5.3.4 Deglycosylation-assay 
 
5 g of crude membrane fraction was incubated either with PNGase F or with Endo H 
and corresponding reaction buffers according to protocol provided by the manufacturer 
(NewEngland BioLabs, Ipswich, USA). After incubation, proteins were subjected to precast 
SDS-polyacrylamide gels.  
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5.3.5 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 
First, 30 g of cell lysates or 5 g of crude membrane fraction were resuspended in a 
sample buffer, containing 10 % DTT and 1x GF® LDS Sample Buffer (4x). Second, samples 
were incubated at 70 °C for 10 min. Third, proteins were separated in precast SDS-
polyacrylamide gels with 10%, 3-8 % or 7 % of acrylamide concentrations (NuPage® 10 % 
Bis-Tris Gel, NuPage® 3-8 % Tris-Acetate Gel and 7 % Tris-Acetate Gel from Invitrogen), 
depending on the protein size of interest (see table 12), in combination with one of the 
following running buffers: NuPage® MOPS SDS Running Buffer (20x), NuPage® MES SDS 
Running Buffer (20x) and NuPage® Tris-Acetate SDS Running Buffer (20x) from Invitrogen. 
Running time for gel electrophorese varied, depending on protein size of interest, gel and 
running buffer (Table 11). 
 
 
Table 11: Gels with different acrylamide concentration were used for SDS-PAGE depending on protein size of interest. 
10% gels 3-8 % gels 7 % gels 
Detection of BiP, HSP90, Calnexin, 
Caspase 3 and 4 in whole cell lysates 
Detection of ABCA3 protein in 
whole cell lysates 
Detection of ABCA3 protein in crude 
membrane fraction including deglycosylation 
assay 
 
 
5.3.6 Western Blotting 
 
Western Blotting was performed according to the wet-blotting method that permits 
reliable transfer of bigger and hardly transportable proteins.  
First, PVDF-membranes were activated with methanol for 10 sec followed by washing 
in distilled water for 30 sec. Second, outer chambers of a wet blotting system were cooled 
with ice and the inner chamber was filled with transfer buffer (10 % methanol, 80 % distilled 
water and 10 % Transfer Buffer (20x) from Invitrogen). Proteins were transferred to PVDF-
membranes at 220 mA in two hours. Third, depending on primary antibodies, washing and 
blocking buffers were prepared specifically as recommended by the manufacturer. 
WesternBreeze® kit was used for detection of GFP-protein.  
Fourth, after protein transfer membranes were washed three times for 10 min in a 
washing solution (PBS, TBS or WesternBreeze® depending on the primary antibody). Fifth, 
membranes were blocked for one hour in blocking buffer, prepared specifically as 
recommended by the manufacturer (blocking buffer I: 10% skin milk powder, PBS or TBS; 
blocking buffer II: 10 % BSA, PBS or TBS) at room temperature followed by an overnight 
incubation at 4 °C in primary antibody diluted in blocking buffer. Sixth, the membranes were 
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washed again three times for 10 min in washing solution, incubated for one hour in a 
secondary antibody in blocking solution at room temperature and washed again three times 
for 10 min in washing solution.  
Seventh, for the chemiluminescent visualization, ELCTM Western Blotting Analyses 
System was applied as recommended by the manufacturer. Chemiluminescence detection 
was performed with Diana III camera system.  
 
 
5.3.7 Liposome preparation and NBD-lipid uptake 
 
Liposome preparation and NBD-lipid uptake were performed following previously 
published protocols (57). Liposomes ( 100 nm) containing C12-NBD-PC or C12-NBD-PE were 
prepared by mixing lipids in chloroform in the following molar ratios: L- DPPC : C12-NBD-PC 
: egg PC : egg PG : cholesterol = 5:5:5:3:2 and L- DPPC : egg PC : egg PG : cholesterol : 
C12-NBD-PE = 10:5:3:2:2. Cells grown on coverslips were transfected with pUB6-HA vectors 
expressing ABCA3 WT or one of the three mutations. 48 h later cells were incubated for 2 h 
with liposomes so that the final concentration of C12-NBD-PC or C12-NBD-PE in the medium 
was 150 μM. Cells were washed three times with PBS and prepared for immunofluorescence 
with primary monoclonal rat anti-HA-tag antibody (1:200, Roche) and secondary anti-rat IgG 
Alexa Fluor 555 antibody (1:200, Invitrogen). NBD-lipid uptake was examined with an 
Olympus FluoView FV 1000 confocal microscope.  
 
 
5.3.8 RNA isolation from A549 cells 
 
A549 cells were grown to 2.4x 105 cells/ 6 well and were transfected 8 hours later. 
Where necessary, incubation with 10 g/ml of tunicamycin (TM) was started 24 hours after 
transfection. 48 hours after transfection, RNA was isolated with the help of High Pure RNA 
Isolation Kit and DNase I, RNase free according to manufacturer´ s recommendation. 
Isolated RNA was stored at – 80 °C and when necessary, thawed on ice. 
 
 
5.3.9 RT-PCR 
 
SuperScriptTMIII First Strand Synthesis System for RT-PCR was used to generate 
cDNA on total RNA template isolated from A549 cells.  Reactions, containing 1 g of total 
RNA and oligo (dT)-primers, were performed according to the manufacturer´ s protocol. To 
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exclude genomic DNA contamination of RNA template a negative control without addition of 
reverse transcriptase (RT) was performed for each sample. To amplify gene of interest, PCR 
was conducted with gene specific primers and 5 l of DNA-product. Table 12 shows optimal 
parameters for RT-PCR. 
 
Table 12: Optimal cycling parameters for RT-PCR in this study. 
Time Temperature Cycles 
5 min 95 °C 1 
20 sec. 95 °C 35 
20 sec. 65 °C 35 
45 sec. 72 °C 35 
5 min 72 °C 1 
 4 °C 1 
 
 
To obtain the level of basal protein expression, PCR was also performed with a 
housekeeping specific primer. PCR products were subjected to a 3% agarose gel. The 
results were considered positive and were statistically evaluated, when no PCR-bands 
appeared in reactions without addition of RT. 
 
 
5.3.10 Densitrometric analysis of the intensity of protein and DNA bands 
 
First, chemiluminescence detection of proteins separated by Western Blotting was 
performed with Diana III camera system (Raytest). Second, the amount of proteins or the 
amount of DNA separated on agarose gels was evaluated by densitrometry with the help of 
the software AIDA. The relative band intensity of the protein or DNA band was obtained 
through normalization to the intensity of a housekeeping protein or gene.  
 
 
5.3.11 Immunofluorescence 
 
Cells were grown on coverslips and after 24 hours these cells were transfected either 
with pEYFP-ABCA3- or with pUB6-ABCA3-HA- vector. 48 hours after transfection, cells were 
fixed and permeabled by methanol incubations at room temperature for 10 min and were 
washed three times with D-PBS buffer. Unspecific binding sites were blocked by blocking 
buffer (containing D-PBS, 3 % BSA and 10 % FBS) for 30 min. Cells were incubated in 
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primary antibody (Table 6) diluted in blocking buffer for one hour. After incubation, samples 
were washed three times with D-PBS and incubated in secondary antibody, either a green- 
or red-fluorescent antibody (Table 7), in blocking buffer for 30 min. All further steps were 
performed in dark. After incubation, samples were washed again three times and coverslips 
were fixed on a microscope slide with Vectashield Hard and Set Mounting Media (Vector 
Laboratories, Burlingame, USA), containing DAPI that stains DNA and is a brilliant blue-
fluorescent marker for cell nuclei.  
For immunofluorescence analysis samples were evaluated with the help of 
Fluorescence microscope Axiovert 135 with filter sets R/B/G and filter set FRET and with the 
software AxioVision Release 4.7.1. 
 
 
5.3.12 FACS analyses 
 
A549 cells were transfected with pEYFP-ABCA3-Wt, -R43L, -R280C or –L101P and 
were grown to 70 % confluence. Cells were gated in the FL-1 channel (YFP-positive 
population of cells). Apoptosis was determined using different approaches. Early apoptosis 
was assayed by 1) measuring intracellular glutathione (GSH) levels with the cell-permeable 
monochlorobimane (Sigma) method and 2) by annexin V+/propidium iodide (PI)- staining 
(Cy5-conjugated anti-annexin V and PI; BD Pharmingen), and late apoptosis was determined 
via intracellular active caspase 3 levels (PE-conjugated anti-active-caspase 3; BD 
Pharmingen) in cells permeabilized with the IntraPrep kit (Beckman Coulter, Krefeld, 
Germany) according to manufacturer’s protocol. To exclude unspecific binding isotype 
controls for caspase 3 and negative controls for glutathione and annexin V/PI staining were 
applied. BD FACSCanto II Flow Cytometer was used for the assay and FACSDiva v6.1.3 for 
data analyses (BD Bioscience). 
 
 
5.3.13 Statistical analyses 
 
Statistical analysis was performed by one-way ANOVA and Bonferroni’s test using 
GraphPad Prism version 4.0 (GrapPad Software Inc., San Diego, CA). All results were 
presented as means +SEM of minimum four experiments and p-values < 0.05 were 
considered significant. 
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6. Results 
 
6.1 Creating a model system to analyse the effect of ABCA3 mutations on alveolar 
type II cells´ homeostasis 
 
In attempt to elucidate how the overexpression of R43L, R280C and L101P mutant     
ABCA3 protein impair homeostasis of human type II pneumocytes, the first part of the study 
was concentrated on creation of a plasmid vector carrying WT ABCA3 cDNA, on introduction 
of point mutations and on generating a cell system that can be easily transfected with a high 
efficiency.  
 
 
6.1.1 Generation of pUB6-hABCA3 vector and site-directed point mutagenesis 
 
 With intention to detect and exclude any effect of YFP-protein expression on 
intracellular ABCA3 protein localization, another plasmid vector carrying WT ABCA3 cDNA 
was created and subsequent used for transfection into A549 cells and for 
immunofluorescence studies. For this purpose, pJet1/hABCA3-HA, carrying HA-tag fused to 
C-terminal of the ABCA3 gene, was used as a starting vector from which ABCA3-HA cDNA 
was cloned into puB6/lacZ (Fig.13, 14). 
 
 
 
 
Fig.13: Vector map of pUB6-hABCA3-HA-WT  
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Fig.14: Vector map of pEYFP-ABCA3-WT 
 
To investigate the effect of R43L, R280C and L101P mutant proteins on human 
alveolar type II pneumocytes, these point mutations were created by site-directed point 
mutagenesis into pUB6-hABCA3-HA and pEYFP-ABCA3 vectors. The results of cloning and 
subsequent site-directed point mutagenesis were confirmed by enzymatic restriction and 
sequencing (Fig.15 and 16).  
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Fig.15: Analysis of pUB6/hABCA3-HA-WT, -R43L, R280C and –L101P plasmids.  
Analysis of pUB6/hABCA3-HA-WT in lane 1-3, of pUB6/hABCA3-HA-R43L in lane 4-6, of pUB6/hABCA3-HA-R280C in lane 7-9 
and of pUB6/hABCA3-HA-L101P in lane 10-12 on a 0.8 % agarose gel. Plasmid DNA was restricted either with Bgl II (lane 2, 5, 
8, 11) giving two chains (6273 bp and of 4269 bp) or with Hind III (lane 3, 6, 9, 12) linearizing the vector (10542 bp). Not 
restricted vectors are shown in lane 1,4,7,10. 
 
 
 
 
Fig.16: Analysis of pEYFP/ABCA3-WT, -R43L, R280C and –L101P plasmids.  
Analysis of pEYFP/ABCA3-WT in lane 1 and 2, of pEYFP/ABCA3-R43L in lane 3 and 4, of pEYFP/ABCA3-R280C in lane 5 and 
6 and of pEYFP/ABCA3-L101P in lane 7 and 8 on a 0.8 % agarose gel. In lane 1,3,5 and 7 plasmids are not restricted. Plasmid 
DNA restricted with Fsp I is shown in lane 2,4,6 and 9, giving four chains (3614 bp, 3130 bp, 2811 bp, 591 bp). 
 
 
6.1.2 Optimization of transfection procedure in A549 cell line 
 
Transfection of plasmid DNA into A549 cells was performed with the help of ExGen 
500 from Fermentas. To achieve best transfection efficiency, the protocol provided by the 
manufacturer was varied. For this purpose, four ExGen/ DNA ratios from 1:5 - 1:8 were 
tested. Transfection efficiency of vectors carrying ABCA3 cDNA was examined in parallel to 
transfection efficiency of a small reference vector pmax-GFP from AMAXA. Best results were 
achieved with an ExGen/ DNA ratio of 1:6 and subsequent incubation. After the mixture was 
incubated at room temperature for 10 min and was added to the cells, the plate with cells 
was not centrifuged, as originally recommended by the manufacturer. For pmax-GFP, 
transfection efficiency was 80 %, whereas for pEYFP-ABCA3 and pUB6-hABCA3-HA it was 
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20 % at most. The low transfection efficiency can be explained by difficulties in transfection 
of the huge vector size accompanied by the huge size of the ABCA3 gene. Transfection 
efficiency was controlled at different time points. 12, 24, 48 and 72 hours after transfection, 
ABCA3-WT protein localization was determined to lamellar bodies (LB). For further 
experiments, cells were collected 48 hours after transfection to ensure enough time for 
general protein turnover in presence and influence of mutant ABCA3 proteins (Fig.17). 
 
 
 
 
 
 
 
 
Fig.17: Immunofluorescence studies in A549 cell line, transiently transfected with pEYFP-ABCA3-WT.  
 
 
6.2 General characterization of R43L, R280C and L101P ABCA3 mutations  
 
In the first part of the study, important preliminary work was accomplished: a vector 
containing WT ABCA3 cDNA tagged with HA was created and introduction of point mutations 
into pUB6-hABCA3-HA and pEYFP-ABCA3 vectors was performed. In addition, a protocol 
for transient transfection of A549 cells was established, being an essential precondition for 
the following investigation of type II pneumocytes´ homeostasis influenced by ABCA3 mutant 
proteins.  
Three clinically relevant ABCA3 mutations identified in patients with neonatal surfactant 
deficiency (R43L and L101P) and chronic pILD (R280C) were chosen for the study. While 
cell biology of R43L and R280C mutations has not been studied yet, L101P mutation was 
previously described as a trafficking/folding defect resulting in the ER retention of L101P 
protein. L101P mutation was deliberately chosen for this study as a cause for the ABCA3 ER 
retention. As so far Matsumura and colleagues (61) have described two categories of 
mutations, general characterization of the new mutations R43L and R280C was assessed by 
determination of the intracellular protein localization and analysis of protein expression, 
processing and glycosylation. 
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6.2.1 Localization and trafficking 
 
Previous studies showed localization of the ABCA3 transporter to the limiting 
membrane of lamellar bodies (LBs) in lung alveolar type II-cells (41). In order to investigate 
ABCA3 protein localization or possibly impaired protein trafficking in A549 cells, staining of 
different cell compartments was performed in parallel with staining of the ABCA3 protein. 
Following compartments were analysed: First, LBs were stained with the marker LAMP3, an 
integral part of membranes of LBs. Second, the ER, important for protein processing and 
quality controlling, was marked by calnexin, an ER-bound chaperone that is involved in 
quality control of protein folding within the UPR system (see “Introduction”), in order to 
elucidate if ABCA3 mutant proteins might be retained in the ER due to processing or folding 
defect. Third, as the Golgi apparatus is an integral part of processing, sorting and 
modification of proteins delivered from the ER, ABCA3 mutant protein localization to this cell 
compartment was assessed as well via the marker GM130. GM130 codes for a protein that 
participates in forming and maintaining cis-Golgi and that supports vesicular transport. 
Fourth, early endosomes were detected via EEA-1, a protein that binds phosphatidylinositol-
3-phosphate in endosomes membranes. Endosomes are formed via endocytosis and plasma 
membrane invagination and transport proteins to lysosomes for subsequent digestion.  
To double confirm ABCA3 protein localization in A549 cells and to rule out possible 
influence and effect of YFP-expression, colocalization studies were performed in parallel with 
pEYFP-ABCA3 vector and pUB6-hABCA3-HA vector. Effects that could have been expected 
in case of YFP-ABCA3 expression were protein aggregation, impaired protein trafficking and 
protein degradation. The intracellular protein localization of ABCA3 protein was determined 
48 hours after transfection. Fluorescence microscopy of A549 cells expressing either type of 
ABCA3 protein fusions showed no differences in protein behavior depending on the type of 
the vector or the size of the protein tag. YFP-ABCA3 WT protein was completely localized to 
LBs (Fig.18). ABCA3 WT protein appeared as a ring-like and dot-like structure in 
immunofluorescence (Fig.18). The colocalization of WT with the ER protein calnexin, GM130 
and EEA1 was not present (Fig.18B, 19, 20). Similar was observed in the case of R43L 
mutant, which gave a vesicular signal that overlapped with LAMP3 fluorescence (Fig.18A) 
and showed no colocalization with calnexin, GM130 and EEA1 (Fig.18B, 19, 20). R280C 
protein colocalized frequently with LAMP3, however the colocalization was not absolute, 
often showing cytoplasmic distribution that overlapped with the fluorescence of calnexin 
(Fig.18, A and B). L101P mutation did not show any vesicular signal at all (Fig.18A) but it 
presented with a net-like cytoplasmic fluorescence colocalizing with the ER protein calnexin 
(Fig.18B). Further immunofluorescence studies showed no localization of L101P mutant 
protein with markers for Golgi apparatus or early endosomes (Fig.19, 20).  
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This suggests correct localization of the WT and R43L transporters in the LAMP3-
positive (LAMP3+) vesicles and retention of the L101P mutant in the ER, possibly as a result 
of protein misfolding. Dual localization of R280C protein might be a sign of hindrance in the 
processing and folding of this mutant which slows down but does not abolish its progress 
through the ER, Golgi and toward LAMP3+ vesicles. As no differences in the intracellular 
ABCA3 protein localization were found in A549 cells transfected with plasmid vectors 
expressing ABCA3-YFP (pEYFP-N1/ABCA3) or ABCA3-HA-tag (pUB6-HA/ABCA3), further 
experiments were performed with pEYFP-ABCA3 vector because it was easier to control the 
transfection efficiency with this self-fluorescent vector prior to further experiments. 
      
Fig.18: Intracellular localization of the WT and mutant R43L, R280C and L101P ABCA3 proteins (I). A549 cells were transiently 
transfected with pEYFP-N1/ABCA3 vectors expressing WT or one of the three mutations. YFP fluorescence of ABCA3-YFP 
fusions (green) was used to detect ABCA3 WT and R43L, R280C and L101P proteins. Colocalization of the ABCA3-YFP signal 
with immunofluorescence of (A) lysosomal/lamellar body protein LAMP3 and (B) ER protein calnexin (both red) are shown. WT 
and R43L localized in LAMP3
+
 vesicles, R280C in LAMP3
+
 vesicles and partially in the ER and L101P completely in the ER. C. 
Partial ER localization of HA-tagged R280C in A549 cells transfected with pUB6/HA-R280C plasmid confirms the R280C ER 
retention as independent of the type of plasmid or protein tag. Representative pictures are shown. Scale bars: 5 μm. 
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Fig.19: Intracellular localization of the WT and mutant R43L, R280C and L101P ABCA3 proteins (II). A549 cells were transiently  
transfected with pEYFP-N1/ABCA3 vectors expressing WT or one of the three mutations. YFP fluorescence of ABCA3-YFP 
fusions (green) was used to detect ABCA3 WT and R43L, R280C and L101P proteins. Golgi apparatus was marked with 
GM130 (red). Colocalization of the ABCA3-YFP signal with immunofluorescence of the Golgi apparatus was not present in WT 
or mutants. Representative pictures are shown. Scale bars: 5 μm. 
 
 
 
 
 
 
Fig.20: Intracellular localization of the WT and mutant R43L, R280C and L101P ABCA3 proteins (III). A549 cells were 
transiently transfected with pEYFP-N1/ABCA3 vectors expressing WT or one of the three mutations. YFP fluorescence of 
ABCA3-YFP fusions (green) was used to detect ABCA3 WT and R43L, R280C and L101P proteins. Colocalization of the 
ABCA3-YFP signal with EEA1, the immunofluorescence signal of early endosomes (red), was not present in WT or mutants. 
Representative pictures are shown. Scale bars: 5 μm. 
 
 
Several authors report localization of ABCA3 WT protein in LBs. To provide an 
additional confirmation of ABCA3 WT protein localization to LBs, it was tested if ABCA3 WT 
protein colocalizes with surfactant protein C (SP-C) that is stored within LBs. For this 
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purpose, A549 cells were cotransfected with pcDNA4-To-ABCA3-HA-WT and pEGFP-N1-
SPC-WT vectors and immunofluorescence studies were performed. As a result, almost 
complete colocalization of ABCA3 WT protein and SP-C WT protein was found forming dot-
like structures (Fig.21). This result confirms that ABCA3 WT and SP-C WT proteins do 
colocalize to LAMP3 positive dot-like structures in alveolar type II cells. 
 
Fig.21: Intracellular colocalization of ABCA3 WT and SP-C WT protein. A549 cells were transiently cotransfected with pcDNA4-
TO-ABCA3-HA-WT and pEGFP-N1-SPC-WT vectors. GFP fluorescence of SP-C fusions (green) was used to detect SP-C WT. 
Absolute colocalization of the SP-C-GFP signal with immunofluorescence of HA-tagged ABCA3-WT (red) is shown confirming 
the ABCA3 localization to lamellar bodies. Scale bars: 5 μm. 
 
 
 
6.2.2 ABCA3 WT and mutant protein processing and maturation in A549 cells 
 
Since incomplete LB-localization of R280C mutant and absolute ER-storage of L101P 
mutant, indicating a strong misfolding and processing defect, further investigation on ABCA3 
protein expression was performed. In immunoblots, two protein bands (180 kDa and 
220 kDa), 30 kDa bigger than previously observed in not labeled ABCA3 constructs (57, 61) 
due to the presence of the 30 kDa yellow fluorescent protein (YFP), were immunodetected in 
ABCA3 WT, R43L and R280C by anti YFP/GFP antibody in transiently transfected A549 
cells (Fig.22A). The processing of ER retained L101P protein was different showing complete 
lack of the 180 kDa band, in line with published data (57, 61, Fig.22A). However, it can be 
concluded that absence of 180 kDa protein band in L101P mutant protein is a strong 
indicator for impaired protein processing, suggesting that ABCA3 cleavage is an essential 
step for ABCA3 protein maturation and subsequent trafficking. New data showed that the 
150 kDa protein band is possibly the mature ABCA3 transporter and necessary for its 
functionality (34). Generation of the lower 150 kDa band in R43L and R280C mutants as 
observed in ABCA3 WT is necessary for at least partial ABCA3 function.  
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6.2.3 Glycosylation of ABCA3 protein 
 
After Western Blotting analysis of cell lysates from cells expressing ABCA3 protein, 
demonstrating that ABCA3 WT, R43L and R280C mutant proteins are expressed as 220 kDa 
and 180 kDa forms, whereas 180 kDa protein is not detectable in L101P mutant (Fig.22A), 
further investigation on ABCA3 processing was performed.  
Glycosylation is an enzymatic process within the ER and Golgi, which links 
saccharides to immature proteins to produce glycans. ABCA3 is a glycoprotein that obtains 
high-mannose oligosaccharides inside of the ER and complex oligosaccharides by 
modification of high-mannose oligosaccharides in the Golgi. Processing of oligosaccharides 
and protein progress down the ER-Golgi maturation pathway was analyzed by 
deglycosylation of the membrane fractions from the A549 cells expressing WT and three 
mutations with two endoglycosidases EndoH (cleaves only high-mannose sugars) and 
PNGaseF (cleaves high-mannose and complex sugars) (Fig. 22B). Immunoblotting with anti-
GFP antibody revealed absence of complex sugars in L101P protein that was susceptible to 
both enzymes, PNGaseF and EndoH, resulting in both cases in a single shifted 
deglycosylated 210 kDa band and no 220 kDa band. Both sugar types were present in WT, 
R43L and R280C proteins, as visible by the resistance of a portion of the 220 kDa band to 
the EndoH treatment. The 180 kDa band was resistant to deglycosylation (Fig.22B). These 
results also additionally confirm the localization studies showing retention of the L101P 
mutant in the ER and ability of WT, R43L and R280C to progress further from the ER to the 
Golgi.        
 
 
A       B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.22: Processing of the WT and mutant R43L, R280C and L101P ABCA3. (A) Immunodetection with anti-GFP antibody 
showed two ABCA3 protein bands (180 kDa and 220 kDa) in whole cell lysates of A549 cells expressing WT and R43L and 
R280C mutations, and only one protein band in the cells expressing L101P mutation. (B) Deglycosylation assay with PNGaseF 
and EndoH on the membrane fractions from A549 cells transfected with pEYFP-N1/ABCA3 plasmids and subsequent ABCA3-
YFP immunodetection with anti-GFP antibody showed presence of high-mannose and complex oligosaccharides in WT, R43L 
and R280C proteins, as well as only high-mannose and no complex oligosaccharides in the L101P mutant resulting from the 
L101P ER retention. 
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6.2.4 Functional assay 
 
Trafficking/ folding defect and ER accumulation of L101P protein exclude the ABCA3 
function in the case of this mutant. However, R43L and R280C mutation are mostly (R280C) 
or completely (R43L) correctly localized and potentially functional (Fig.18, A and B). 
Therefore, a functional study of uptake of fluorescently NBD-labeled lipids into the lamellar-
body-like vesicles in A549 cells transfected with pUB6-HA/ABCA3 plasmids was performed 
(Fig.23). Liposomes containing NBD-labeled major surfactant phospholipid phosphatidyl-
choline (C12-NBD-PC) and NBD-labeled minor surfactant phospholipid phosphatidylethanol-
amine (C12-NBD-PE) were incubated with A549 cells expressing WT, R43L, R280C and 
L101P HA-tagged proteins. L101P mutant was used to monitor the situation with 
nonfunctional ABCA3 protein. Colocalization of the fluorescent signal of C12-NBD-PC and 
C12-NBD-PE (green) with ABCA3-HA-positive vesicles (red), which normally colocalized with 
LAMP3 (Fig.18, A and B), was monitored by confocal microscopy.  
Interestingly, uptake of fluorescent liposomes into A549 cells was prominent in all 
cells, including those expressing L101P mutants (Fig.23) and therefore without ABCA3 
function and untransfected A549 (data not shown), showing numerous NBD-positive 
vesicular structures dispersed throughout the cytoplasm (Fig.23). This confirms that 
lipid/liposome uptake into the cytoplasm through the plasma membrane does not depend on 
functional ABCA3, and that ABCA3 is solely an intracellular vesicular lipid transporter.  
WT-ABCA3-HA signal formed ring-like structures, consistent with the localization of 
ABCA3 in the limiting membrane of lamellar bodies. Both NBD-PC and NBD-PE fluorescent 
signals were often visible as a punctual signal merging with this ring-like border of WT-
ABCA3-HA vesicles (Fig.23, A-C). Also, accumulation of the weaker diffuse green NBD 
signal was frequently observed within the inner space of WT-ABCA3-HA vesicles (Fig.23C 
and Fig.23, A and B - small sections). NBD is a fluorophore characterized by extremely fast 
photobleaching and we suppose that uptake and packing of a bigger amount of this 
fluorescent dye into the WT-ABCA3-HA vesicles might cause self-quenching of the 
fluorescence. Another possible reason for this effect is a diffuse distribution of the limited 
amount of NBD-phospholipids within the vesicles, which makes the signal less pronounced. 
Similar colocalization of NBD fluorescence with ABCA3-HA vesicles was extremely rarely 
observed in the cells expressing R43L and R280C mutations (Fig.23, A and B). This 
indicates ability of WT-ABCA3-HA vesicles to take up and accumulate both fluorescent lipids, 
while R280C-ABCA3-HA and R43L-ABCA3-HA vesicles did not show such ability. 
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6.2.5 Biogenesis of LAMP3+ vesicles induced by ABCA3-WT protein expression 
 
Expression of WT or three mutations exhibited different effects on biogenesis of the 
LAMP3+ vesicles in A549 cells. To elucidate the effect of ABCA3 expression on LB 
biogenesis in AT II cells, the amount of LBs was assessed in ABCA3 Wt and mutants. A549 
cells normally show a low number of small LAMP3+ vesicles, but expression of WT-ABCA3 
induced biogenesis of many big vesicles with ring-like signals of ABCA3 fluorescence 
(equally from pEYFP-N1 or pUB6-HA vectors). Expression of R43L, R280C and L101P 
mutations exhibited a negative effect on vesicle formation and induced a lower number of 
smaller compact LAMP3+ vesicles, with the most drastic effect in L101P mutant (Fig.24). This 
again proves the role of ABCA3 in lamellar body biogenesis as previously described (55, 57, 
58). Decreased uptake of NBD fluorescence in lamellar bodies and impact on lamellar body 
biogenesis together suggest functional impairment of the R43L and R280C proteins.  
 
Fig.23: Functionality of the R43L and R280C transporters. A-C, uptake of C12-NBD-
phospholipids PC and PE into ABCA3 vesicles in A549 cells transfected with 
pUB6/HA-ABCA3 vectors was studied by confocal microscopy. Transfected cells 
were incubated for 2h with C12-NBD-PC (A) and C12-NBD-PE (B) containing 
liposomes (150 μM of NBD-lipid). HA-tag was used to detect ABCA3 WT and R43L, 
R280C and L101P by immunofluorescence (red). Both C12-NBD-PC and C12-NBD-
PE fluorescence (green) frequently colocalized with the ring-like ABCA3 WT signal 
as well as within the ABCA3-WT vesicles and almost never with the R43L and 
R280C vesicles. In small sections and in (C) uptake into ABCA3-WT vesicles of both 
NBD-lipids PC and PE is shown closer. Uptake through the plasma membrane into 
the cytoplasm of L101P transfected cells with no functional exogenous ABCA3 was 
observed as well as numerous cytoplasmic NBD-positive liposome-like vesicles in all 
A549 cells independent of the ABCA3 mutation (A and B). Scale bars: 5 μm 
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Fig.24: Influence of WT ABCA3 and three mutations on biogenesis of LAMP3
+ 
vesicles in A549 transfected with pUB6/HA-
ABCA3. WT ABCA3 (green) induced biogenesis of LAMP3
+ 
vesicles (red) increasing their number and size in A549 cells, while 
R43L, R280C and L101P proteins showed no such effect (the same was observed in A549 pEYFP-N1/ABCA3 transfected cells 
- not shown). Representative pictures are shown. Scale bars: 5 μm. 
 
 
 
 
6.3 Induction of ER stress by mutant ABCA3 expression  
 
In the first two parts of this study, general characterization of the clinical relevant 
mutations R43L, R280C and L101P was performed by identification of the intracellular 
protein localization to LBs or ER (Fig.18) and analysis of glycosylation pattern of ABCA3 WT 
and mutant proteins (Fig.22B). Since these ABCA3 mutations caused a decrease of LB 
numbers, further studies were performed to elucidate how these mutants disturb cell 
homeostasis of AT II cells. 
However, a model, in which misfolded proteins cause cell injury and cell death through 
disruption of the quality control system (see “Introduction”), was supported by a study on 
misfolded SP-C. It was shown that ER protein accumulation and cytostolic aggregate 
formation of some SP-C mutations induced ER stress and subsequent apoptotic cell death 
(106). Based on these results, the aim of this study was to analyse cellular response to 
mutant ABCA3 protein expression as previously demonstrated for SP-C mutations, 
especially in terms of ER chaperones and apoptotic markers. 
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6.3.1 L101P and R280C mutation upregulate ER stress marker BiP 
 
BiP/Grp78 is an essential ER chaperone of Hsp70 family, which assists translocation 
of a nascent protein chain into the ER and its subsequent folding. When misfolded proteins 
accumulate in the ER, BiP upregulation is one of the first signals of the ER stress and allows 
further UPR activation (116). The effect of ABCA3 mutations on chaperones is especially 
interesting since until now ER stress-induction has not been investigated in ABCA3 mutants. 
Immunoblotting of whole cell lysates from A549 cells expressing ABCA3-WT and 
three mutants revealed upregulation of BiP chaperone in the case of the L101P and R280C 
mutations in comparison to WT (Fig.25, A and B), caused by complete (L101P) and partial 
(R280C) ER retention of these two mutated ABCA3 transporters (Fig.18). No significant BiP 
increase was detectable between WT and correctly localized R43L mutation. While treatment 
of A549 cells with a potent ER stress-causing antibiotic tunicamycin (TM) caused drastic BiP 
upregulation in A549 cells, differences measured between WT and three mutations were 
more subtle differences. 
 
A 
 
 
B 
 
 
Fig.25: ER stress chaperone BiP. A, A549 cells with ER retained L101P mutant or partially ER retained R280C protein showed 
upregulation of the immunodetected ER chaperone BiP in comparison to WT and A549 cells. BiP was drastically upregulated 
after 14h treatment of A549 cells with 10ug/ml of ER stressor tunicamycin (TM). B, intensity of each protein band was 
densitometrically quantified and normalized to the corresponding ß-actin band. Densitometric quantification of the BiP protein 
level of four independent experiments, without inclusion of drastic effect of TM treatment, is presented; * p<0.05, * * p<0.01. 
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6.3.2 ABCA3 mutants influence expression of Hsp90 
  
Heat shock protein family provides an intracellular response for general protection 
against protein aggregation in the cytosol. These proteins promote the conformational 
maturation of a large variety of proteins into three-dimensional structures. Hsp90 is the most 
prominent of the heart shock proteins in the cell with 1-2 % of all cytosol proteins.  
The intracellular amount of Hsp90 was analysed in whole cell lysates of A549 cells 
transiently transfected with pEYFP-ABCA3-WT, -R43L, -R280C and -L101P by 
immunoblotting. The amount of Hsp90 in R43L mutant was comparable to that in WT, 
whereas in both R280C and L101P mutants, stronger protein band intensity was obtained 
(Fig.26). Fine differences between WT and mutations can be explained by only 20 % 
transfection rate. But the increase of Hsp90 protein expression in R280C and especially in 
L101P, together with increased BiP protein expression, suggest that these ABCA3 mutants 
have significant impact on cell homeostasis and initiate the UPR system. 
 
A:     
B:               
Fig.26: ER stress chaperone Hsp 90. A, A549 cells with ER retained L101P mutant or partially ER retained R280C protein 
showed slight upregulation of the immunodetected ER chaperone Hsp90 in comparison to WT and A549 cells. In R43L mutant, 
Expression of ER-chaperone Hsp90 was as low as in WT. B, intensity of each protein band was densitometrically quantified and 
normalized to the corresponding ß-actin band. Densitometric quantification of the Hsp90 protein level of four independent 
experiments is presented. 
 
  
 
6.3.3 No influence on calnexin expression by ABCA3 mutations 
 
Moreover, together with a number of other chaperones, calnexin facilitates protein 
folding by catalyzing intra- and inter-molecular disulfide bond formation to prevent trafficking 
of unfolded proteins to Golgi apparatus and further downstream in the secretory pathway, 
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rather retained in the ER lumen. In attempt to elucidate any effect of mutant ABCA3 protein 
on calnexin expression, the whole cell lysates of A549 cells transiently transfected with 
pEYFP-ABCA3-WT, R43L, R280C or L101P were prepared and analyzed by immunoblotting 
using an anti-calnexin antibody (Fig.27A). As a result, calnexin expression did not change 
significantly between WT and mutations. Having only 20 % transfection rate possibly 
influenced the measurements of fine differences and smaller changes as well.  
 
 
A   
B       
Fig.27: ER stress chaperone calnexin. A, A549 cells with ABCA3 WT and three mutations showed no upregulation of the 
immunodetected ER chaperone calnexin. B, intensity of each protein band was densitometrically quantified and normalized to 
the corresponding ß-actin band. Densitometric quantification of the calnexin protein level of four independent experiments is 
presented. 
 
 
 
6.3.4 L101P and R280C mutation increase susceptibility of A549 cells to the ER stress  
 
In this study it was recognized that ABCA3 mutant proteins disturb cell homeostasis 
in A549 cell line via induction of ER stress assessed by chaperone BiP, particularly in case of 
partially (R280C) and complete (L101P) ER-retained mutations (Fig.25). Upon ER 
accumulation of misfolded proteins BiP dissociates from the luminal domain of IRE1, allows 
IRE1 dimerization and synthesis of active XBP1 protein, a UPR transcription factor, which 
regulates expression of ER stress proteins including BiP. XBP1 activation is regulated on the 
level of splicing of 26 nt intron from the XBP1 mRNA by endoribonuclease activity of the 
IRE1 dimer (82-84).  
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To confirm the observations made on the ER chaperone level, splicing of the XBP1 
mRNA was assayed by RT-PCR as described by Hybiske and colleagues (117). Two 
approaches were applied to analyze XBP1 splicing. In a first experiment, 48 hours after 
transfection, A549 cells were analyzed for XBP1 splicing via RT-PCR and in a second 
experiment to intensify the stress, transfected cells were additionally incubated with 10 ng/ml 
of tunicamycin (TM) for 13 hours.  
First, the ratio of spliced (s; 500 bp – 26 bp) and unspliced (u; 500 bp) XBP1 RT-
PCR bands was determined, prior and after the treatment of the PCR products with PstI 
restriction endonuclease, as a measuring control. Slower migrating hybrid (h) band of 
unspliced and spliced single-stranded DNAs produced during PCR, and thus equally 
contributing to unspliced and spliced bands, was observed as well after the long-run 
separation on 3 % agarose (84, Fig.28A). Tunicamycin treatment strongly increased the 
intensity of the spliced PCR band in A549 cells in comparison to untreated A549 (Fig.28B). In 
A549 cells with either WT or one of the three mutations, increase of XBP1 splicing was 
measured only in the case of L101P mutation (Fig.28A). Probably because of the robustness 
of the method and 20 % transfection rate, finer differences between WT and R43L and 
R280C were not observable, and the effect was measurable only in the case of the L101P as 
the strongest defect (Fig.28A).  
Second, in attempt to imitate that in nature lungs are not exclusively affected by 
ABCA3 mutations but also exposed to outside stress factors such as viral infection and 
smoking, and to investigate the susceptibility of cells with ABCA3 mutations to external ER 
stress-causing agents, transfected cells were exposed to 10 mg/ml of tunicamycin, an 
inhibitor of N-linked glycosylation (Fig.28, D and E). The outcome of such double internal 
genetic and external tunicamycin pressure on XPB1 splicing was examined. Tunicamycin 
treatment strongly induced XBP1 splicing with the comparable effect in A549 and WT cells 
(Fig.28D). However, after exposure to tunicamycin XBP1 splicing was considerably more 
pronounced in R280C and L101P mutations if compared to A549 cells with WT and R43L 
mutations (Fig.28, D and E). Obviously, although XBP1 splicing was measurable only for the 
strongest L101P defect under non-stimulated condition, cells with L101P and R280C 
mutations were significantly more prone to further elevation of ER stress upon exposure to 
an external stressor (Fig.28, D and E).  
These results demonstrate that through mimicking outer stress, ABCA3 mutants do 
change normal protein cell biology and disturb cell homeostasis of AT II cells more 
significantly by raising the level of intracellular stress and susceptibility to it. Furthermore, 
these results suggest that presence of outside stress factors has an additional impact on 
cellular response to ABCA3 mutants in AT II cells. 
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Fig.28: Susceptibility of A549 cells with ABCA3 mutations to ER stress measured by XBP1 splicing. XBP1 activation during 
UPR is regulated on the level of splicing of a 26 nt intron from the XBP1 mRNA. A, XBP1 splicing in untransfected A549 cells 
with and without tunicamycin (TM) treatment (10 mg/ml, 14 h) and in A549 cells with R43L, R280C and L101P mutations. Two 
PCR products were detected by RT-PCR: u - unspliced and s - spliced XBP1 bands. h denotes a hybrid band between 
unspliced and spliced ssDNA produced during PCR and observed after long-run separation on 3 % agarose (upper panel) (21). 
For easier densitometric evaluation and to ensure good separation between unspliced and hybrid band, half of the PCR 
products were cut by PstI endonuclease which cuts only unspliced (u) band giving two bands u1 and u2 (middle panel). Control 
reactions without reverse transcriptase (+/-RT) and 18S rRNA (lower panel) are shown as well. B and C, densitometric 
quantification of the bands (s, u) from the upper panel (no PstI) and the middle panel (shown in the graph; PstI digest), 
presented as the ratio s/u (no PstI) or the ration s/u1+u2 (PstI digest). TM highly elevated XBP1 splicing in A549 cells (A). 
Lower effect of L101P mutation on XBP1 splicing in A549 cells and no effect in A549 with WT and R43L and R280C mutations 
were observed (B and C). D and E, as in A-C: TM treatment of all A549 cells expressing ABCA3 mutations (10 mg/ml, 14 h) 
strongly induced XBP1 splicing in all cells, with the most significant increase in A549 expressing R280C and L101P mutations in 
comparison to the WT+TM or A549+TM. After exposure to TM almost no unspliced bands (u1 and u1) were observed, only 
increase in spliced (s) bands in R280C and L101P mutations. Shown are the 3 % agarose after the PstI digestion of the RT-
PCR products (upper panel) and 18S rRNA (lower panel) (D) and the densitometric evaluation of the bands (E). Presented 
graphs are the densitometric quantification of four independent experiments; * p<0.05, ** p<0.01.  
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6.4 L101P and to a lesser extent R280C mutation induce apoptosis of A549 cells  
 
Constant accumulation of defect proteins within the ER and activation of the UPR 
system affect significantly cell homeostasis: As demonstrated, R280C- and L101P- 
expressing cells revealed elevated BiP levels and XBP1 splicing, particularly in the presence 
of additional ER stressor, indicating that these mutants perturb homeostasis of ATII cells by 
raising the level of the intracellular stress and susceptibility to it (Fig.25, 28). Prolonged and 
unresolved ER stress accompanied by constant UPR activation and its failure can lead to 
increased degradation of defect proteins, reduced general protein synthesis or initiating of 
pro-apoptotic pathway (see “Introduction”). Since it was shown that SP-C mutations, 
accumulated in the ER or cytosol, induce ER stress and subsequent apoptotic cell death (94, 
106), it was interesting if ABCA3 mutations impair this fatal stress/apoptosis/cell-dysfunction 
axis as well. Activation of the apoptotic pathway in cells expressing ABCA3 mutants was 
assessed by early and late apoptotic markers: annexin V/PI staining, GSH decrease and 
caspase 3 activation.  
 
 
 
6.4.1. Annexin V/PI staining 
 
In apoptosis, pro-apoptotic activation of caspase 3 can change characteristics of the 
plasma membrane and leads to externalization of phophatidylserines (PS) (97). The exact 
mechanism how caspase 3 interacts with phospholipid translocation is not completely 
understood to the date. However, the expression of PS on the cell surface of dying cells is a 
signal for macrophages to capture these cells for phagocytosis (118). Annexin V specifically 
binds to the surface-exposed PS of apoptotic cells and is used as a marker of early 
apoptosis. Besides, a marker for late apoptosis and necrosis is propidium iodide (PI) that 
binds to double-stranded DNA, but only in non-viable cells that have lost membrane integrity. 
In order to experimentally investigate whether both early apoptosis and necrosis might be 
induced by ABCA3 mutants, flow cytometry was performed to analyse annexin V staining of 
cells expressing ABCA3 defect proteins and to analyse PI staining within these cells.  
For this purpose, A549 cells were transiently transfected with pEYFP-ABCA3-WT -
R43L, -R280C or L101P and 48 hours after transfection, samples were prepared for flow 
cytometry. Flow cytometry assay of Cy5-coupled Annexin V surface binding showed an 
increase in the number of annexin V+/PI- cells in transfected YFP+ cells in the case of R280C 
and L101P mutations when compared to WT and R43L indicating early apoptotic state of 
those cells (Fig. 30A). 
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6.4.2. GSH decrease 
 
Glutathione is an essential low-molecular-weight thiol and a major component of the 
cell antioxidant system. Loss of intracellular GSH is an early hallmark of apoptosis 
progression and a part of early changes for generation of a permissive environment for the 
activation of apoptotic enzymes (119). For this purpose, A549 cells were transiently 
transfected with pEYFP-ABCA3-WT -R43L, -R280C or L101P and 48 hours after 
transfection, samples were prepared for flow cytometry. YFP fluorescence was utilized to 
determine the population of transfected cells (YFP+) and to measure the apoptotic markers 
exclusively in those cells. Intracellular GSH level, measured by flow cytometry of 
monochlorobimane binding to GSH and generation of a fluorescent adduct, was significantly 
decreased in the YFP+ cells with L101P protein compared to YFP+ WT, and to a lower extent 
compared to R43L and to R280C (Fig.30B).  
 
 
 
6.4.3. Caspase 3 activation 
 
Pro-apoptotic pathway is initiated by active caspases, a family of highly conserved 
proteases present in the cell as inactive precursors and activated through a cascade of 
regulated proteolytic cleavages leading to controlled cell death (91, 120). Among 15 known 
members in mammalian species, caspase 3 is one of the executioner caspases activated at 
the end of the cascade. Therefore, activation of caspase 3 is a late apoptotic marker. For this 
purpose, two approaches were applied and active caspase 3 was measured by Western 
Blotting as well as by flow cytometry. 
First, an increase of caspase 3 activation in cells expressing the ER-retained L101P 
mutant in comparison to WT and R43L was observed via flow cytometry assay of intracellular 
active caspase 3 (Fig. 30C). R280C values showed steady increase in caspase 3 activation, 
however with lower significance than L101P (Fig. 30C).  
Second, to confirm this observation, active caspase 3 was additionally measured by 
immunoblotting. A549 cells were transiently transfected with pEYFP-ABCA3-WT, -R43L, -
R280C and –L101P and after 48 hours the whole cell lysates were prepared and analyzed by 
immunoblotting using an antibody, that detects the pro-form of caspase 3 (32 kDa) as well as 
the active forms of caspase 3 (19 and 17 kDa). Cells, expressing R43L, R280C or L101P 
mutant proteins, revealed clearly elevated levels of active caspase 3. Especially in L101P 
expressing cells the amount of active caspase 3 was significant higher than in WT (Fig.29). 
These results confirm data obtained by FACS. 
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Fig.29: Early apoptosis marker caspase 3. A, A549 cells with ER retained L101P mutant showed upregulation of the 
immunodetected active caspase 3 in comparison to WT. B, intensity of each protein band was densitometrically quantified and 
normalized to the corresponding ß-actin band. Densitometric quantification of the active caspase 3 protein level of three 
independent experiments is presented; * p<0.05. 
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Fig.30 Apoptosis in A549 cells expressing L101P and R280 mutations. A549 cells were transfected with pEYFP-N1/ABCA3 
plasmids and apoptotic markers were analyses by FACS in transfected (YFP
+
) population of cells and A549 cells by assaying 
(A) annexin V
+
/propidium iodide (PI)
-
 staining and (B) intracellular (i.c.) glutathione (GSH) level with coupling of 
monochlorobimane with GSH, to determine early apoptosis, and (C) intracellular active caspase 3 level (MFI), to detect late 
apoptosis. Elevated early and late apoptotic markers were detectable in cells expressing L101P mutation, and one early marker 
(Annexin V) in cells expressing R280C mutation. Results were calculated from six independent experiments; * p<0.05, ** 
p<0.01, *** p<0.001.  
 
 
In summary, while R43L mutation did not raise apoptotic signaling above the A549 or 
WT level, R280C mutation increased one early apoptotic marker and ER-localized L101P 
mutations significantly elevated early and late apoptotic markers, indicating injury of the cells 
with L101P protein. 
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6.4. Prolonged ER stress leads to apoptosis through caspase 4 activation in cells 
expressing R280C and L101P mutations  
 
To examine if initiation of apoptosis in cells with ABCA3 mutations is indeed a 
consequence of the ER stress signaling, cleavage of caspase 4, which is activated by ER 
stress specific stimuli in a mitochondria and cell death receptor-independent way (93, 94), 
was assessed. Cleavage of caspase 4 leads to proteolytic activation of executioner 
caspase 3 and to cell elimination (95). Therefore, activation of caspase 4 identifies ER stress 
as an apoptosis trigger.  
In attempt to elucidate if these ABCA3 mutants induce pro-apoptotic pathway in an 
ER stress depending manner, caspase 4 was analyzed in whole cell lysates of A549 cells 
transiently transfected with pEYFP-ABCA3-WT, -R43L, -R280C and –L10P by 
immunoblotting. The anti-caspase 4 antibody detected the pro-form at 42 kDa and two 
cleaved forms.  
Treatment of A549 cells with apoptosis inducing cytokine TNF  resulted in the 
cleavage of caspase 4 (Fig.31, A-C). Immunoblotting of whole cell lysates from the cells 
expressing WT or R43L, R280C or L101P mutations showed insignificant changes in pro-
caspase 4 level between WT and mutations, but the level of pro-caspase 4 was somewhat 
higher in transfected cells than in A549 cells (Fig.31B). In contrast, cleaved caspase 4 in 
R280C and L101P mutants increased significantly in comparison to WT. Changes measured 
between R43L and WT were not significant (Fig.31C). This shows that caspase 4 is involved 
in apoptotic signaling in cells with L101P and R280C mutations and that activation of the 
apoptotic pathway can be a consequence of the ER stress caused by complete or partial ER 
retention of the ABCA3 protein. 
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Fig.31: Apoptotic signaling in cells with L101P and R280C mutations is activated by ER stress. A, immunoblotting on whole cell 
lysates from A549 cells transfected with pEYFP-N1/ABCA3 and densitometric analyses of (B) pro-caspase 4 and (C) cleaved 
caspase 4 demonstrated increased caspase 4 cleavage in cells expressing L101P and R280C mutations, as well as after TNF  
treatment of A549 (25 ng/ml, 16 h) in comparison to WT and untreated A549. No significant changes in the pro-caspase 4 level 
in transfected cells with WT, R43L, R280C and L101P mutations were detected but pro-caspase 4 was slightly increased in 
transfected cell compared to A549 (B).  - unknown unspecific band. Intensity of each protein band was densitometrically 
quantified and normalized to the corresponding ß-actin band. Six independent experiments were used for densitometric 
evaluation; * p<0.05, ** p<0.01. 
 
 
6.5 Epithelial-mesenchymal transition in A549 cells expressing ABCA3 defect proteins 
 
Increasing evidence indicates a connection of fibrogenesis and epithelial apoptosis in 
the pathogenesis of interstitial lung disease (103, 107, 108). When lung tissue is injured, the 
consequent lung repair requires an additional source of myofibroblasts and fibroblasts (110, 
121, see “Introduction”). However, it was discovered that epithelial alveolar type II cells can 
undergo epithelial-mesenchymal transition (EMT), thereby changing their morphology and 
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cell characteristics towards myofibroblast like cells and contributing to fibrogenesis via TGF-ß 
and cytokine secretion (109, 114). 
 To the date, it was not yet investigated if alveolar type II cells with defect ABCA3 
protein contribute significantly to fibrogenesis in the lungs. Therefore, it was interesting, to 
test if AT II cells expressing R43L, R280C and L101P mutants that were identified to cause 
unresolved ER stress (Fig.25, 28) and to induce apoptosis (Fig.29-31) undergo EMT in AT II 
cells. 
 
 
6.5.1 Induction of epithelial-mesenchymal transition in A549 cell line 
 
It is well known that some key factors like Tissue Growth factor ß1 (TGF-ß1) are 
responsible for transition of epithelial cells to myofibroblasts and fibroblasts and effect cell 
characteristics and morphology in vitro (109, 114). In order to characterize and confirm the 
transition to mesenchymal phenotype in AT II cells, the effect of TGF-ß1 on A549 cell line 
was analzed by two approaches: first, analysis of the mesenchymal marker vimentin and 
second, analysis of the epithelial marker E-cadherin. 
First, A549 cells were incubated with different concentrations of TGF-ß1 to determine 
optimal concentrations of TGF-ß1 to induce EMT in this cell line. For vimentin analysis, A549 
cells were cultured in RPMI+ 10 %FBS for 24 hours as usual. Treatment with various 
concentrations of TGF-ß1 (0.05 ng/ml –5.0 ng/ml) was performed in serum free RPMI for 
additional 24 hours. In whole cell lysates, expression of vimentin was examined by 
immnuoblotting. As a result, in not treated as well as in treated A549 cells, vimentin was 
detected. Through TGF-ß1 concentrations of 0.05 ng/ml, 0.5 ng/ml and 5.0 ng/ml, there was 
an steady increase in vimentin expression in comparison to not treated A549 cells (Fig.32), 
whereas vimentin levels were at their highest at 5.0 ng/ml of TGF-ß.  
Second, ECAD only appeared in A549 cells that were cultured under standard 
conditions (Fig.33). In cell lysates of A549 cells treated with 0.05 and 0.5 ng/ml of TGF-ß1 
and cultured in serum free media, ECAD disappeared (Fig.32). These results demonstrate 
that EMT can take place in alveolar type II cells and suggest that TGF-ß activated alveolar 
type II cells may contribute to pulmonary fibrogenesis. 
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Fig.32: Induction of EMT in A549 cell line through different concentrations of TGF-ß1. A, A549 cells showed upregulation of the 
immunodetected marker of myofibroblasts vimentin through increasing TGF-ß1 concentrations. B, densitometric quantification 
of the vimentin protein level is presented. 
 
 
 
 
Fig.33: ECAD in A549 cell line in absence and presence of TGF ß1. A549 cells showed lost of immunodetected ECAD under 
TGF ß1-treatment. 
 
 
6.5.2 Induction of epithelial-mesenchymal transition in A549 expressing ABCA3 defect 
protein 
 
Given that fibrosis is a common manifestation in genetic ILDs and that alveolar type II 
cells contribute significantly to fibrogenesis, it was interesting to investigate if R43L, R280C 
and L101P ABCA3 mutations make alveolar type II cells more prone for transdifferentiation 
into myofibroblast like cells, thereby contributing to fibrogenesis in the lung. For this reason, 
vimentin and ECAD were analyzed in the whole cell lysates of A549 cells, transiently 
transfected with pEYFP-ABCA3-WT, -R43L, -R280C or -L101P by immunoblotting.   
As a result, in cells expressing ABCA3 WT, R43L, R280C or L101P mutants, the 
epithelial marker ECAD was present (Fig.34). Furthermore, as shown for untransfected A549 
cells (Fig.32), vimentin appeared in ABCA3 WT expressing cells as well as in mutants. 
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However, vimentin revealed no difference in cells with ABCA3 WT or with the three 
mutations (Fig.34). This result can be explained by the low transfection efficiency and less 
time for transfected cells to undergo EMT. However, these data are indicators that in stable 
transfected cells, alveolar type II cells might undergo EMT in response to disturbed cell 
homoeostasis perturbed by ABCA3 defect protein. 
 
 A         
B                
Fig.34: ECAD and vimentin in A549 cells expressing ABCA3 WT or mutant proteins. A, A549 cells showed no differences in 
immunodetected vimentin and ECAD in WT or the three mutations. B, intensity of each protein band was densitometrically 
quantified and normalized to the corresponding ß-actin band. Densitometric quantification of the vimentin protein level of three 
independent experiments is presented. 
 
 
 
Considering the fact that alveolar epithelial cells release various profibrotic cytokines 
and growth factors (see “Introduction”) thereby contributing to the induction of EMT in 
epithelial lung cells and fibrogenesis, it was experimentally tested if ABCA3 mutants induce 
EMT in AT II cells under additional stimulation with TGF-ß1. 
Therefore, A549 cells were transiently transfected with pEYFP-ABCA3- WT, -R43L, -
R280C or –L101P and 24 hours after transfection, these cells were additionally incubated 
with 0.5 ng/ml of TGF-ß1 for further 24 hours. The whole cell lysates were prepared and 
analysed via immunoblotting using an anti-vimentin antibody. As a result, vimentin was 
slightly increased in cells with R43L and R280C mutations and being at its highest in L101P 
mutation (Fig.35).  
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Fig.35: Marker of myofibroblasts vimentin in A549 cells expressing ABCA3 WT or mutant proteins under additional stimulation 
with 0.5 ng/ml of TGF-ß1. A, A549 cells with ER retained L101P mutant showed upregulation of the immunodetected marker of 
myofibroblasts vimentin in comparison to WT. B, intensity of each protein band was densitometrically quantified and normalized 
to the corresponding ß-actin band. Densitometric quantification of the vimentin protein level of three independent experiments is 
presented; * p<0.05.  
 
 
 
In conclusion, under additional stimulation with TGF-ß1, imitating autocrine or 
paracrine cellular stimulation in the lungs, vimentin was upregulated in alveolar type II cells 
with ABCA3 defect proteins, especially in A549 cells with ER-retained L101P defect protein. 
These results suggest that these mutations push cells toward transdifferentiation into 
myofibrobalsts contributing to fibrogenesis in the lungs and pathogenesis of ILD. 
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7. Discussion 
 
ABCA3 mutations cause surfactant deficiency and fatal respiratory distress syndrome 
in full-term neonates and chronic ILD of children (21, 22, 63-73). The cellular 
pathomechanisms of ABCA3-related chronic ILD are probably complex including influence of 
ABCA3 mutations on surfactant homeostasis but possibly also on the fitness and function of 
alveolar type II cells as cells for surfactant production, lung repair and immunological defense 
(122).  
In this study the influence of three ABCA3 mutations, R43L, R280C and L101P, on 
intracellular stress and induction of apoptosis in cultured lung epithelial A549 cells was 
investigated. All three mutations were found in children with ABCA3-associated lung disease 
being either fatal neonatal respiratory distress syndrome (L101P (22) and R43L (28, 48)) or 
chronic ILD (R280C (48, own unpublished data) (Table 2). While cell biology of R43L and 
R280C mutations was studied here for the first time, L101P mutation was used as a known 
example of the trafficking/folding defect leading to the ER retention of ABCA3 with no 
information on ER stress (57, 61). 
 
 
7.1 General characterization of the three ABCA3 mutations R43L, R280C and 
L101P 
 
The general characterization of R43L, R280C and L101P ABCA3 mutant proteins 
included the analysis of the intracellular localization, of protein processing and glycosylation 
and an uptake assay of NBD-labeled phospholipids PC and PE. To the date, ABCA3 
mutations are either known for a functional defect and for impaired protein trafficking (61).  
Improper protein folding, failed trafficking and mislocalization are well recognized in 
other diseases associated with mutations in ABC transporters. For example in Tangier 
Disease, a genetic HDL- deficiency, caused by defect ABCA1 transporter, the ABCA1 
mutations R587W and Q597R are mainly retained in the ER instead of being transported to 
the plasma membrane accompanied by impaired processing of oligosaccharides (123). 
Moreover, in Cystic Fibrosis caused by mutations in the ABCC7 gene encoding an ABC 
transporter, named cystic fibrosis transmembrane conductance regulator (CFTR) (124), the 
most common mutant ΔF508 is retained and destroyed in the ER by the ER quality control 
system and failed trafficking to plasma membrane (125). 
Initial characterization in A549 cells demonstrated that each of the mutations 
analyzed in this study affect the ABCA3 transporter in a different way. It was shown the 
correct localization of WT and R43L proteins in LAMP3+ vesicles and dual localization of 
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R280C protein in LAMP3+ vesicles and calnexin+ ER compartment (Fig.18-20), indicating 
less efficient but not abolished R280C trafficking. Similar dual localization is known in the 
case of other ABCA3 mutants as G122S (57). However, L101P mutant protein appeared as 
a net-like structure without any vesicle structures and LAMP3 colcoalization but complete 
storage in the ER (Fig.18), as previously described (61).  
Previous studies have analyzed ABCA3 localization to LBs by using LAMP3 staining 
as well (59). In attempt to confirm additionally the localization of ABCA3 WT protein to LBs 
and to show normal alveolar type II physiology in A549 cells used in this study, the 
colocalization of ABCA3 WT protein and SP-C WT protein, that is stored within LBs, was 
demonstrated in A549 cells expressing both proteins simultaneously (Fig.21). 
ABCA3 protein expression was analyzed in alveolar type II cells by immunoblotting of 
whole cell lysates and of the crude membrane fractions. Previously, ABCA3 protein 
expression was described in human and mice tissues as well as in different cell lines. The 
appearance of ABCA3 as one or two protein bands by immunoblotting depended on the 
species and antibody, which were used (28, 58, 59). But recently, the lower protein band was 
recognized as the mature one (34). In this study, when a yellow fluorescent protein (YFP) of 
30 kDa was fused to ABCA3 protein, both protein bands, cleaved and noncleaved forms, 
were present in cell cultures when ABCA3 WT was overexpressed (Fig.22). Similar 
processing was observed for R43L and R280C proteins (Fig.22). Considering the fact of 
correct LB localization of R43L mutant protein assessed by immunofluorescence studies, it 
was not surprising to find WT-processing and presence of complex oligosaccharides 
(Fig.22). In the case of YFP-R280C mutant protein, when dual localization to LAMP3+ 
vesicles and ER compartment was found, it was interesting to detect similar protein 
processing and presence of complex oligosaccharides in this mutation as before in WT and 
R43L mutation (Fig.22), confirming their ability to proceed from the ER to the Golgi.  
In contrast, L101P protein remained in the ER, having therefore no complex sugars, 
and no smaller 180 kDa protein form (Fig.22), as previously published (57, 61). This data 
demonstrate a strong processing and glycosylation defect in L101P mutant protein. 
 In summary, these results suggesting the presence of oligosaccharides in ABCA3 WT 
and R43L are consistent with proper immunofluorescence localization studies. However, in 
terms of R280C mutation, the similarity of ABCA3 processing and protein glycosylation to 
WT and R43L mutation makes a functional defect most likely, being in lane with 
immunofluorescence studies when R280C was mainly localized to LBs. In case of L101P 
mutant, absent oligosaccharides are consistent with failed trafficking and the ER-localization 
demonstrated in this immunofluorescence studies as well as with strong processing 
deficiency confirmed through absent cleaved form in Western Blotting. It can be speculated 
that L101P mutant increases ER stress due to its processing defect and ER-storage. 
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Following this prediction ER stress was assessed in all mutants.  
While ER retention of L101P excludes ABCA3 function, the function of R43L and 
R280C transporters was studied additionally. As ABCA3 is involved in lamellar body 
biogenesis in lung cells (22, 55, 60), which normally have a low number of compact LAMP3+ 
vesicles, expression of ABCA3-WT induced biogenesis of LAMP3+ vesicles by increasing 
their number and size in A549 cells (59, Fig.24). In addition, ABCA3-WT signal was observed 
as ring-like structures consistent with the ABCA3 presence in the limiting membrane of 
lamellar bodies (41, Fig.18, 24). In contrast to the WT, expression of ABCA3 mutations, 
especially L101P, impaired biogenesis of LAMP3+ vesicles by reducing their number and 
size (Fig.24). This can be a consequence of the inability of these mutated transporters to 
effectively load lipids into the nascent lamellar bodies.  
 The uptake assay of NBD-labeled phospholipids PC and PE into ABCA3-HA-positive 
vesicles demonstrated frequent overlap of the NBD signal, both PC and PE coupled, with the 
ring-like ABCA3-WT fluorescence and its accumulation in the inner space of the WT-ABCA3 
vesicles (Fig.23). In the case of R43L and R280C mutations such colocalization was rarely 
observed suggesting functional impairment of R43L and R280C proteins. Similar uptake 
experiments have been previously described (57). In contrast to those data, which showed 
diffuse distribution of NBD-PC and NBD-PE fluorescence throughout the cytoplasm, 
numerous distinct NBD-positive vesicles were detected (Fig.23, A and B). The uptake and 
number of NBD-vesicles observed in the cytoplasm was similar for both phospholipids in 
A549 cells and in transfected A549, and was also independent of the ABCA3 mutation, 
including L101P. This confirms that for the liposome/lipid uptake through the plasma 
membrane into the cytoplasm ABCA3 function is dispensable and ABCA3 is solely an 
intracellular vesicular transporter. Furthermore, we observed an impact of ABCA3 mutations 
on the uptake of both PC and PE. This parallels data published in Cheong et al. (2007) (55) 
which demonstrated decreased incorporation of radiolabeled PC and PE into the lamellar 
bodies and surfactant of the ABCA3 heterozygote mouse, consistent with a role of ABCA3 in 
the transport of both phospholipid species. However, this is also in contrast to Cheong et al. 
(2006) (57) showing no uptake of NBD-PE into the lysosome-like vesicles in A549 cells. 
Therefore, it is questionable if the PE transport through functional ABCA3 actually happens 
in vivo or only in in vitro system after exposing cultured A549 cells to 150 μM of NBD lipid.
  
  
 
 
 67 
7.2 Induction of ER stress and UPR system by ABCA3 mutants 
 
Continuous overload of the ER compartment with misfolded proteins is harmful for the 
cell and leads to activation of the UPR system (126). Misfolding and ER retention of other 
lipid ABC transporters is well known (123, 125). The most common mutation F508 of the 
ABCC7-transporter, leading to cystic fibrosis, is not only misfolded and therefore retained in 
the ER, it also raises ER stress and activates UPR (127). Also in SP-C deficiency, the 
mutations exon4 and L188Q, which are retained in the ER or form aggregates in the 
cytoplasm, induce UPR activation (94). But also in other organs than the lung, accumulation 
of mutant protein in the ER cause toxic effects and cellular injury via ER stress, particularly 
via BiP upregulation, as in liver and lung disease caused by 1-AT deficiency (128) and 
neuronal degenerating diseases (129). 
According to recent in vitro studies on cells expressing mutant ABCA3 proteins it 
could have been speculated that dysfunction of the ATP-dependent lipid transporter resulting 
in modified composite of surfactant components may give evidence for the mechanism how 
mutant ABCA3 proteins disturb cell homeostasis and causes RDS or pILD (56, 59, 60). In 
contrast, this study on human lung epithelial cell line A549 overexpressing mutant ABCA3 
protein showed previously not examined cellular dysfunction, including raised level of 
intracellular stress, susceptibility to it and induction of pro-apoptotic pathway: 
 Since L101P protein accumulates in the ER, it was not surprising to find significant 
increase of the ER stress (Fig.25-28). Upregulation of chaperones is in line with ER 
localization and defect protein glycosylation, indicating a strong misfolding defect and a 
strong effect on induction of ER stress. Especially, splicing of XBP1 mRNA goes along with 
subsequent upregulation of BiP caused by the misfolding defect of L101P mutant protein. 
The ER stress caused by R280C mutation was lower. This might be a consequence of a dual 
nature of this protein, which could be less harmful for the cell than complete ER retention, 
and/or possible dependency of the magnitude of its intracellular effects on small 
unmanageable inconsistencies of an experimental system. Correctly localized R43L 
mutation, despite its influence on the ABCA3 function and lamellar body biogenesis, had 
almost no impact on ER stress under any conditions above the range of the WT values 
(Fig.25-28), being in lane with proper localization and processing studies and indicating less 
cellular disturbance. However, the low increase of ER stress in cells with R43L or R280C 
defect proteins might be due to low transfection efficiency of 20 % and to the robustness of 
the method.  
Since in nature, lungs are not exclusively affected by mutant ABCA3 protein but also 
by environmental conditions such as dust, smoking, infection and hypoxemia that cause 
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additional intracellular stress, ER stress and UPR activation, examined via XBP1 splicing, 
were enhanced by exposure of transfected cells to tunicamycin, an ER stressor 
(Fig. 28, D and E). In this way the stress pressure imposed on the cells was doubled: 1) 
genetic background of the ABCA3 mutations and 2) exposure to the stress-causing agent. 
The cells with mutations R280C and L101P, which impair ABCA3 trafficking, were more 
prone to further XBP1 splicing than the WT or A549 (Fig.28D). This is interesting if known 
that viral infections (e.g. RSV, herpes virus) or cigarette smoke are common outside factors, 
which, as tunicamycin, elevate ER stress (130, 131). Also clinical experts report from the 
onset of ABCA3-associated ILD in children following exposure to cigarette smoke (68) and 
describe a teenage patient with a late onset of ABCA3-related disease with fibrosis following 
the beginning of cigarette consumption (71). If ABCA3 mutations raise susceptibility of 
alveolar type II cells to external stress, additional exposure to outside stressors as respiratory 
viral infections or smoke might contribute to or even trigger genetic ILD.  
 
 
7.3 Induction of apoptotic cell death by ABCA3 mutations 
 
Constant accumulation of defect proteins within the ER lumen and activation of the 
UPR system disturb cell homeostasis, cause cell toxicity and disruption of cell function. 
Furthermore, prolonged and unresolved ER can trigger apoptotic cell death (see 
“Introduction”). Recently, upon accumulation of mutant SP-C protein in the ER and also in 
model systems for other conformational diseases like Parkinson´ s disease, the mechanism 
of ER stress and subsequent apoptotic cell death was found in vitro (106, 132). However, in 
patients with IPP/IFP alveolar epithelial cells were identified to undergo apoptosis, whereas 
apoptosis was absent in control lungs (133, 134).  
In this study, the connection between the overexpression of ABCA3 mutations and 
induction of apoptotic cell death was analysed by three lines of evidence: activation of 
caspase 3, either via immunoblot or via FACS, PI and annexin V staining. Since L101P 
protein accumulation in the ER increased stress response elements, early and late apoptosis 
markers were also recognized in the cells with this mutation (Fig.29, 30). The ER stress 
caused by R280C mutation was lower and therefore surface staining with annexin V, as an 
early apoptosis sign, was the only apoptotic marker detected in R280C cells. Correctly 
localized R43L mutation, despite its influence on the ABCA3 function and lamellar body 
biogenesis, had almost no impact on stress and apoptosis under any conditions above the 
range of the WT values (Fig.29, 30).  
 
 69 
 
 
Fig.36: Hypothesis of early and late onset of lung disease caused by ABCA3 mutations. Impaired ABCA3 transporter function is 
accompanied by disturbed surfactant composition and acute respiratory distress syndrome in newborns. Late onset of pediatric 
ILD might be caused by increased intracellular stress and apoptosis, exacerbated by outer stressors as infection or cigarette 
smoke. The author of this model is Dr. Suncana Kern, she provided it to our research group and I use it with her permission. 
 
 
Prolonged accumulation of misfolded proteins and unresolved ER stress are 
connected with the activation of apoptotic pathway in a caspase 4-dependent way (see 
“Introduction”, (94). The link between ER stress and induction of apoptosis in cells, 
overexpressing ABCA3 mutations, was established through the upregulation of caspase 4 in 
the case of both L101P and R280C mutations (Fig. 31). As expression of R43L mutant 
protein shows no impact on ER stress, correctly localized R43L mutation, was not associated 
with caspase 4 cleavage above the range of the WT values (Fig.31). 
Given to the low transfection efficiency of 20%, the relative induction of apoptosis in 
A549 cells, overexpressing mutant R280C and L101P ABCA3 protein, is highly significant in 
mutants compared to WT. Overexpression of R280C and L101P ABCA3 proteins perturb 
homeostasis of ATII by raising the level of the intracellular stress and susceptibility to it and 
can push them toward apoptotic pathway. This might impair normal function of ATII in lung 
repair, immunological defense and surfactant production and the resulting cell injury may 
contribute to pathogenesis of pILD (Fig.36). 
 
 
7.4 EMT in alveolar type II cells overexpressing ABCA3 mutations 
 
In lungs of patients with ABCA3 deficiency related disease, pathologists found 
features of fibrosis (21, 68, 71). Lung disease with fibrotic foci is believed to be a 
consequence of chronic alveolar epithelial injury and abnormal alveolar repair (107, 110). 
Fibroblastic foci are characterized by mesenchymal cells as fibroblast and myofibroblasts as 
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well as by abnormal extracellular proteins (see “Introduction”). However, pathogenesis of 
pulmonary fibrosis is still poorly understood, but alveolar type II cells seam to have a key role 
in this process (135). Recent studies not only on fibrotic lung disorders, but also on renal and 
liver diseases, showed that epithelial cells can undergo EMT and that TGF-ß plays a key role 
in transition of epithelial cells into mesenchymal cells (114, 136, 137). Epithelial lung cells 
that have undergone EMT may contribute to the development of fibroblastic foci in various 
ways: as a new source of fibroblasts or by the activation and migration of fibroblasts and by 
the release of cytokines and growth factors. However, the precise mechanism of the 
formation of fibroblastic foci and the origin of mesenchymal cells are both incompletely 
understood.  
In this study, it was demonstrated for the first time that A549 cells overexpressing 
ABCA3 mutant proteins, especially L101P cells, gain a mesenchymal phenotype with 
increased expression of vimentin, particularly in presence of TGF-ß1 (Fig.34, 35). It can be 
speculated that the examined ABCA3 mutations make AT II cells more prone to undergo 
EMT. Furthermore, induction of ER stress and apoptosis in these ABCA3 mutations, 
particularly the ER-retained L101P mutation, is associated with induction of EMT in AT II. 
Role of ER stress and apoptosis in lung disease has also been studied by other groups, 
showing that ER stress- and apoptosis- markers occur at sites of fibrosis in alveolar type II 
cells (103, 104, 133, 134). These results suggest that ER stress may contribute to lung 
fibrosis through induction of EMT in ABCA3 related lung disease. Further experiments are 
necessary to support these notions. This mechanism is also believed to underlie in SP-C-
related lung disease (138). SP-C and ABCA3 are both ATII-expressed proteins essential for 
surfactant homeostasis and both lead to genetic ILD equally variable in the age of onset, 
severity and pathology. Therefore, it is interesting to see that common mechanisms 
underlying both types of genetic ILD must exist and this data show that they probably 
encompass the ER stress and apoptosis of AT II cells mediating EMT. Therefore, AT II cells 
with ABCA3 deficiency may have a critical role for development of fibrosis in pILD (Fig.37). 
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Fig 37: EMT in ATII might be a possible mechanism of lung fibrogenesis in children with ABCA3 mutation. ABCA3 mutations 
disturb cell homeostasis and induce ER stress and apoptosis. The resulting cell injury might be a stimulus for endocrine or 
autocrine TGF-ß secretion. TGF-ß stimulates fibroblasts migration and EMT in ATII, thereby promoting pulmonary fibrogenesis. 
Own illustration according to a model of Dr. Suncana Kern. 
 
 
7.5 Conclusion 
 
Apparently, the effect of ABCA3 mutations on homeostasis of lung epithelial cells 
depends on the type of ABCA3 protein defect. With this study it was shown for the first time, 
that the clinical relevant ABCA3 mutations with partial or complete ABCA3 trafficking defect 
raise intracellular stress and susceptibility to it, and induce apoptotic cell death signaling. 
Induction of ER stress and apoptosis as a result of overexpression of some ABCA3 
mutations is accompanied with findings consistent with EMT. Similar as proposed for SP-C 
deficiency, intracellular stress and apoptosis of alveolar type II cells might play a role in 
pathogenesis of ABCA3-related lung disease.  
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7.6 Future directions 
 
This study demonstrated mechanisms, which may contribute to the pathogenesis of 
ABCA3 related lung disease thereby raising new questions that should be addressed in 
future work.  
First, studies on induction of ER stress and apoptosis in ATII cells expressing ABCA3 
mutations should be supplemented by further experiments. Studies on the most common 
E292V mutation, a type II mutation located to LBs with reduced functional activity, would also 
be helpful to confirm findings of ER retained mutation in this study.  
Second, more work is necessary to verify if ER stress and apoptosis of AT II cells are 
indeed present in (fibrotic) lung tissue of patients with ABCA3 mutations. Studies on lung 
tissue from children with ABCA3 mutations could also provide more information on ATII cells 
and their role in pathogenesis of pILD, e.g. in terms of morphology, surfactant homeostasis 
and cytokine and growth factor release.  
Third, exposure to outsides stressor should become a subject of future experiments. 
RSV-infection could be a helpful instrument. Further investigations on the precise pathway of 
how ABCA3 mutant proteins can lead to fibrogenesis and studies on the role of TGF-ß are 
needed. 
This might help to understand or even predict the disease course, or consider new 
therapy options (as protein rescue with chaperones) depending on the type of the ABCA3 
protein defect. Since to date no causative therapy is available for the treatment of pILD, the 
role of chemical chaperones should be tested in vitro for ER-retained ABCA3 mutations.  
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